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ABSTRACT 
 
Triple-negative breast cancer (TNBC) does not express estrogen receptors, progesterone 
receptors, or human epidermal growth factor receptor 2, and it is characterized by its 
aggressive nature, lack of targeted therapies and early peak of recurrence. Recent 
observational research suggests that inactivity is associated with an increased risk of 
breast cancer (BC) including the Triple Negative subtype. Little is known about the 
potential driving molecular events for each subtype of BC and the mechanisms through 
which exercise yields protective effects against disease progression and recurrence risk. 
The present thesis focuses on the protective effects of exercise against TNBC through the 
induction of biochemical metabolic system modifications able to reduce the cell 
proliferation of BC. 
 
Organization of the thesis and experimental approaches 
 
The first chapter provides possible explanations of causative mechanisms for cancer 
control examining recent findings regarding the basic biological effects of exercise on 
modulation of the mTOR pathway in TNBC and the benefits induced by various exercise 
and training protocols. 
The second chapter of the thesis examines how circulating serum factors released after 
exercise (High-Intensity Endurance Cycling (HIEC) Test), before (pre) and after (post) a 
training protocol, could reduce TNBC cell line proliferation, ex vivo. 
The third chapter evaluates the effect of structured and supervised physical activity 
(PA) intervention on breast cancer survivors (BCS) - “Lifestyle program”. 
We showed that PA counseling and supervised exercise training improve functional 
exercise capacity and could motivate subjects suffering from BC to adopt a healthier 
lifestyle based on the maintenance of physical activity levels (PAL) recommended in this 
population. Women enrolled in the “Lifestyle program” took part in the Dragon Boat 
Race Day event, representing the first team of women in pink from the Marche Region. 
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Breast Cancer 
 
Today breast cancer (BC) is the most common invasive tumor in women worldwide and 
is the most common cancer in all age groups, albeit at different rates (41% in young 
women vs. 22% in older women). In Italy, there were an estimated 50,500 new cases in 
2017 and the average 5-year survival rate (87%) in our country is higher than the 
European average (82%) [1]. Studies have shown that BC is the result of an intricate 
interaction among genetic, epigenetic and environmental factors. Among the most 
significant factors influencing the risk of BC onset and relapse are aging, gender, family 
history, inherited factors (mutations in the BRCA1 and BRCA2 genes), menstrual and 
reproductive history, dense breasts, race and ethnicity, radiation exposure, birth control 
pills, combined post-menopausal hormone therapy (PHT), and diethylstilbestrol exposure 
(DES). 
In recent years a growing body of evidence points to the important effect that healthy 
lifestyle choices (modifiable factors) such as not smoking, adopting a healthy diet and 
doing regular PA could have on the onset and clinical course of BC. 
Growing amounts of data indicate a relationship between PA, biological makers of BC 
aggressiveness (e.g., levels of insulin, estrogen and IGF-1, and inflammatory status) and 
lower recurrence risk. 
BC is a heterogeneous disease and differs greatly among patients (inter- intra-tumor 
heterogeneity) [2]. Although in Western countries the incidence of BC is increasing, 
mortality is steadily decreasing mainly due to prevention strategies, including regular 
mammography screenings for early detection of BC and primary prevention based on 
healthy lifestyle choices (not smoking, healthy diet and regular PA). 
Several epidemiological studies suggest that physically active women have a significantly 
lower risk (a reduction of about 25%) of developing BC than sedentary women [3]. 
Exercise could also reduce the side effects of cancer treatments such as chemotherapy, 
radiotherapy and hormone therapy and have a positive effect on psychological wellbeing 
since woman undergoing cancer therapy are more at risk of developing depressive and 
cognitive disturbances [4-6]. Additional positive effects of PA include a reduction in 
body fat, improvement in immune system regulators, alterations in free-radical generation 
and an improvement in the ability of cancer patients and survivors to deal with fatigue, 
lymphedema and bone metastasis [7]. Another important consideration is that, after 
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diagnosis, most BC patients and survivors reduce PA level (by 11%) [8], and sedentary 
behaviors are strongly associated with overweight and obesity, both recognized risk 
factors for BC. Indeed, adipose tissue contributes to the establishment of a systemic low‐
grade inflammatory state characterized by activation and infiltration of pro‐inflammatory 
immune cells and a deregulated production of pro‐inflammatory cytokines [9,10,11]. 
 
Molecular and Systemic Effects Linking Exercise to Cancer Prevention and Cancer 
Control* 
 
It has been 20 years since skeletal muscle was recognized as an endocrine organ, and 
skeletal muscle contraction and myokine release have received attention as exercise-
induced health beneﬁts. Physical activity (PA) has been shown to reduce cancer 
incidence, inhibit tumor growth, and improve clinical outcomes following a diagnosis of 
a primary disease [12], yet daily energy expenditure from PA is decreasing at an alarming 
rate in Western society [13]. In particular, inactivity is associated with an increased risk 
of breast cancer (BC). Pernille Hojman and collaborators from Bente K. Pedersen’s 
research team describe the latest molecular understanding of the systemic effect of 
exercise on cancer progression control. They deﬁned a direct effect on tumor-
environment factors linked to whole-body exercise remodeling, mitigation of cancer-
related adverse events, and amelioration of anti-cancer treatment efﬁcacy. Several 
preclinical studies on the effect of exercise on cancer outcomes point to a reduction in the 
rate of tumor growth [14,15]. However, an important ﬁnding of these studies is that 
exercise, per se, is not capable of directly eliminating already established tumors. For 
example, in response to exercise-conditioned serum treatment, BC cell growth is 
inhibited by 10–15% compared to tumor growth observed in the control setting, but there 
is not a complete eradication of cancer cells [16,17]. Recent investigations have stressed 
the role of circulating growth factors, prohormones, and sexual hormones, which are able 
to stimulate cancer cell proliferation through the activation of their respective receptors 
[18,19]. In particular, the phosphoinositide 3-kinase-AKT-mammalian target of 
rapamycin (PI3K-AKT-mTOR) pathway is a frequently hyperactivated pathway in cancer 
and is important for tumor cell growth and survival. Many studies have shown a down-
regulation of PI3K-AKT-mTOR signaling after exercise; however, to date, none have 
established the exercise-dependent mechanisms underlying this association. Exercise 
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inhibits mTOR functions in both AMPK-independent and -dependent manners. AMPK is 
also induced in tumors during exercise [20,21], probably as a transient condition. It is 
known that intra-tumoral metabolism is regulated, but how this affects tumor growth and 
metastatic rate during exercise is not currently understood. Chronic exercise induces 
physiological adaptation across homeostatic control circuits, such as oxidative 
metabolism, mitochondrial biogenesis in several tissues, angiogenesis, immune 
regulation, and metabolism. Moreover, it diminishes BMI and blood concentrations of 
estrogens, and insulin, decreases insulin resistance, and strengthens anti-inﬂammatory 
pathways against tumor cells. Hence, exercise has an increasingly protective tumorigenic 
effect [22,23]. These ﬁndings have wide-ranging implications for society and may lead to 
improve the way cancer is managed. 
 
Physical Activity Counseling in Breast Cancer Survivors* 
 
The overall prevalence of women living with a diagnosis of breast cancer (BC) is 
increasing in industrialized countries. Survivors who maintain a healthy weight and stay 
physically active (PA) have a better response to treatment and better survival outcomes. 
Thus, it is necessary to identify an appropriate promotion and prescription of regular PA 
for BC survivors to improve their prognosis, response to therapy, and quality of life. In 
this issue, Fong AJ and colleagues [24] examine factors affecting exercise counseling by 
clinicians and discuss future strategies to address oncology clinicians’ perceptions of PA 
counseling and barriers to such counseling in BC survivors. Focus group discussions 
were transcribed verbatim and analyzed using inductive thematic analysis. In order to 
facilitate PA counseling, healthcare facilities, and clinicians need to better support and 
promote patient-managed PA, making it available on multiple platforms and providing 
better referral pathways to exercise professionals and physiologists. 
 
Protocol for Exercise Prescription among Breast Cancer Survivors* 
 
Recent systematic reviews and meta-analyses tend to aggregate exercise programs into 
general categories and rarely investigate the speciﬁc features of these programs, which 
may make them more or less effective. What physical activity (PA) should be prescribed 
for breast cancer (BC) survivors? Not all types of exercise carry the same beneﬁts. 
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Speciﬁcity is a core principle of exercise training to promote the desired adaptations, and 
the speciﬁcity of adaptation is underpinned by the acronym FITT, which stands for 
frequency, intensity, time and type. The FITT principle outlines the key components of 
an effective exercise program Overall recommendations for cancer survivors are 
consistent with the American Cancer Society, who recommends that cancer survivors 
engage in a minimum of 150 weekly minutes of moderate-intensity exercise, and it is 
important to note that the American College of Sports Medicine [25] has established 
FITT guidelines that are easy to follow for exercise prescription that everyone should 
know. Frequency refers to how often exercise is performed, intensity refers to the 
intensity of the exercise undertaken, time refers to the amount of time spent exercising, 
and type refers to the kind of exercise that is performed. However, adherence to any 
exercise program is the most difﬁcult thing to achieve, and currently there is a growing 
number of initiatives designed to increase the effectiveness of long-term PA in BC 
patients in the most comfortable environment: at home. The aim of the study carried out 
by Mascherini G. and collaborators was to verify the long-term effectiveness of a home-
based program for active lifestyle change in overweight BC survivors. They enrolled 
premenopausal women, whose PA levels, baseline aerobic capacity, ﬂexibility, strength, 
and anthropometric measurements were assessed. These parameters were assessed six 
times during one year of unsupervised exercise. After being prescribed an individual 
exercise program, a signiﬁcant reduction in BMI and skinfold sum was observed, as well 
as maintenance of muscle cell mass. Assessments also showed an increase in lower limb 
muscle ﬁtness and a reduction in diastolic blood pressure after a six-minute walking test. 
Exercise is highly recommended for cancer patients, and the prescription of a home-based 
model of unsupervised exercise described by Mascherini G. et al. seems to ensure ideal 
compliance, favoring long-term therapeutic efﬁcacy [26]. This intervention strategy could 
target all patients affected by BC and might motivate these subjects to adopt a healthier 
lifestyle based on regular PA, as well as proper nutrition. 
 
High Intensity Interval Training (HIIT): new evidence in BCS 
 
In recent years, it has been suggested that a reassessment of the exercise prescription 
guidelines for BCS is needed. Generally, the beneficial effects induced by exercise are 
commonly attributed to two types of adaptation, long-term (months/years), such as 
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improvement in cardiorespiratory fitness, strength and body composition [27,28,29] and 
short-term effects (hours/days) due to stimulation of muscle contraction. In particular, the 
marked systemic response to a single bout of exercise reduces the vitality of BC [30]. The 
available exercise guidelines for BCS emphasize the importance of participating in 
moderate aerobic and resistance exercise and recommend flexibility building exercises or 
combined exercises (aerobic and resistance exercise) [31]. However, research on the 
effects of different types of exercise on physical fitness and various biomarkers in BCS is 
ongoing, and in the past year, a great deal of evidence has emerged regarding a novel 
strategy of training for BCS: High-Intensity Interval Training (HIIT). HIIT is a cardio 
session consisting of short sets of intense exertion, and it represents a valid alternative to 
traditional endurance-based exercise training for preventing cardiovascular disease 
(CVD) in BCS [32]. In particular, the principle of HIIT is based upon high intensity 
aerobic exercise training bouts that are separated by periods of lower intensity that allow 
for recovery. The target intensity during HIIT is between 85-95% of peak heart rate 
(HRpeak) for four minutes, while during the two-to-three-minute lower intensity recovery 
periods, the target intensity is between 60-70%. 
Only a few studies have been conducted on HIIT training in BCS where it was shown 
that HIIT can be performed by female cancer survivors without adverse health effects, 
and it may be an effective way to improve certain aspects of health, including protection 
against chronic diseases, especially CDV, in this population. 
The beneficial effects of HIIT consist of improved quality of life, reduced cancer-related 
fatigue [33] and reduces the adverse cardiotoxic effects due to treatments in different 
stage of disease. An ongoing pilot study is examining the HIIT effects on endothelial 
function and maximal oxygen consumption (VO2max) [34]. 
In the HIIT protocol, the exercise training intensity is relative to the individual’s peak 
oxygen uptake (VO2peak) and HRpeak and should be measured for each individual before 
starting a HIIT program to control the exercise training intensity properly. Furthermore, it 
has been shown that VO2max and other cardiovascular efficiency measures, such as 
endothelial function, improve both with HIIT exercise and with higher volumes of 
moderate continuous intensity exercise [35]. Both types of exercise enhance the patient’s 
quality of life (QoL), reduce fatigue, and improve energy expenditure and body 
composition. However, one of the added benefits of HIIT workouts is the reduced time 
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this protocol requires compared to other exercise programs and the fact that there are 
currently no contraindications for its use by BCS. 
  
*A part of the introduction was taken by the Editorial The “Journal of Functional 
Morphology and Kinesiology” Journal Club Series: Highlights on Recent Papers in 
Physical Activity and Sedentary Behavior. Barbieri E, Falcieri E, De Santi M, Natalucci 
V, Vallorani L, Agostini D, Annibalini G, Stefani L, Szychlinska MA and Musumeci G. 
2018. 
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AIMS OF THE THESIS 
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The first aim of this thesis was to provide new evidence of the effects of exercise on 
breast cancer prevention, control and healthy benefits. 
 
The primary outcome of this thesis was to examine if systemic responses to acute 
exercise and training could modulate breast cancer cell proliferation and/or intracellular 
pathways, ex vivo. Particular attention will be focused on the anti-proliferative effect of 
exercise serum on Triple-Negative Breast Cancer cells. 
 
The secondary outcome was an ameliorating effect induced from the introduction of 
targeted exercise counseling and a structured physical activity intervention on functional 
exercise capacities and lifestyle in breast cancer survivors. 
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Abstract  
 
Triple-negative breast cancer (TNBC) does not express estrogen receptor, progesterone 
receptor and human epidermal growth factor receptor 2, and is characterized by its 
aggressive nature, lack of targets for targeted therapies and early peak of recurrence. Due 
to these specific characteristics, chemotherapy does not usually yield substantial 
improvements and new target therapies and alternative strategies are needed. The 
beneficial responses of TNBC survivors to regular exercise, including a reduction in the 
rate of tumour growth, are becoming increasingly apparent. Physiological adaptations to 
exercise occur in skeletal muscle but have an impact on the entire body through systemic 
control of energy homeostasis and metabolism, which in turn influence the TNBC tumour 
microenvironment. Gaining insights into the causal mechanisms of the therapeutic cancer 
control properties of regular exercise is important to improve the prescription and 
implementation of exercise and training in TNBC survivors. Here we provide new 
evidence of the effects of exercise on TNBC prevention, control and outcomes, based on 
the inhibition of the phosphatidylinositol-3-kinase (PI3K)/protein kinase B (PKB also 
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known as Akt)/mammalian target of rapamycin (mTOR) (PI3K-Akt-mTOR) signaling. 
These findings have wide-ranging clinical implications for cancer treatment, including 
recurrence and case management. 
 
 
Keywords 
Exercise, Physical Activity, Cancer control, mTOR, Triple Negative Breast Cancer 
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1. Introduction 
Breast cancer (BC) is one of the most common carcinomas and one of the main causes of 
cancer-related death worldwide [1]. Among the various subtypes, triple-negative BC 
(TNBC) accounts for approximately 20% of BC cases. The absence of estrogen and 
progesterone receptors and human epidermal receptor 2 (HER2) in malignant cells 
reduces treatment options and increases the risk of recurrence and death, especially in the 
first 3–5 years of follow-up after surgery [2]. Thus, TNBC exhibits a more aggressive 
clinical course than non-TNBC. Most TNBC cases are diagnosed in women under the age 
of 60, and in 20% of diagnosed cases, there is a mutation of the germinal BC (BRCA) 
gene [3–7]. In patients with metastatic TNBC, there are currently no available targeted 
therapies and chemotherapy is the only possible treatment option. In addition to the 
biological-molecular aspects associated with prognosis and BC development, a growing 
body of evidence highlights the impact of lifestyle on disease-related outcomes. 
Unhealthy lifestyles with low levels of physical activity (PA) result in overweight and 
obesity, which appear to have a negative impact on BC [8], increasing the risk of 
recurrence and death in all subtypes, including TNBC [9]. Conversely, proper diet, 
weight loss, and increased PA lead to more favourable outcomes in the short and long 
term [10, 11]. The mechanisms underlying the effects of exercise on breast 
carcinogenesis are not clear, but experimental evidence suggests that PA induces 
phosphatidylinositol-3-kinase (PI3K)/protein kinase B (PKB also known as 
Akt)/mammalian target of rapamycin (mTOR) (PI3K-Akt-mTOR) signaling inhibition 
and slows TNBC tumor cell growth [12–14]. Physiological adaptations to exercise occur 
primarily in skeletal muscle, but the effects of exercise and training also impact other 
tissues through systemic control of energy homeostasis and metabolism, thus influencing 
the TNBC tumor microenvironment and mTOR inhibition [15]. 
Given the scope of this review, we summarise recent discoveries related to the underlying 
biology of exercise-induced modulation of the mTOR pathway in TNBC, examining the 
benefits induced by different exercise and training protocols. 
We also consider how exercise affects the level of microRNAs (miRNAs) linked to the 
mTOR pathway involved in TNBC initiation and progression [16, 17], and how nutrients 
can influence mTOR signaling. 
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Finally, we discuss how exercise induces beneficial adaptations and why it should be 
prescribed as a coadjuvant “medicine,” which has the potential to improve TNBC 
outcomes. 
 
 
2. mTOR Signaling 
 
2.1. mTOR Pathway and mTOR Activation in BC 
mTOR is a serine-threonine kinase that interacts with several proteins to form two 
distinct complexes, mTORC1 and mTORC2, which show different sensitivities to 
rapamycin [18]. mTORC1 is acutely sensitive to rapamycin and responds to growth 
factors, stress, amino acids, and energy, promoting protein translation and synthesis, cell 
growth, mass, division, and survival. mTORC1 comprises mTOR, the regulatory 
associated protein of mTOR (Raptor), the G-protein β-subunit-like protein (GβL), also 
known as mLST8, DEP domain-containing mTOR-interacting protein (Deptor), proline-
rich Akt substrate of 40 kDa (PRAS40), and Tti1/Tel2 complex. mTORC2 is insensitive 
to acute rapamycin treatment and contains mTOR, the rapamycin-insensitive companion 
of mTOR (Rictor), the mammalian stress-activated map kinase-interacting protein 1 
(mSIN1), GβL, Deptor, protein observed with Rictor-1/2 (Protor 1/2), and Tti1/Tel2. 
Raptor and PRAS40 are unique to mTORC1, while Rictor, mSIN1, and Protor 1/2 are 
unique to mTORC2 [18]. 
The various components of mTORC1, which is the most widely studied complex, have 
several regulatory effects: Raptor, Tti1, and Tel2 are positive regulators, whereas 
PRAS40 and Deptor are negative regulators [19]. Several factors regulating mTORC1 
activation converge in the tubular sclerosis complex (TSC), consisting of hamartin 
(TSC1), tuberin (TSC2), and TBC1 domain family member 7 (TBC1D7) [20]; the 
complex works via the Ras homolog enriched in brain (Rheb) GTPase, negatively 
regulating mTORC1 [21]. 
An upstream regulator of TSC is the PI3K/Akt pathway activated by growth factors such 
as insulin-like growth factor 1 (IGF-1) and insulin. PI3K phosphorylates 
phosphatidylinositol (3,4)-bis-phosphate (PIP2) lipid to phosphatidylinositol (3,4,5)-tris-
phosphate (PIP3), which recruits phosphoinositide-dependent kinase-1 (PDK1) and Akt. 
Akt phosphorylates TSC2 and PRAS40 inactivating them and inducing, in turn, 
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mTORC1 activation [22]. TSC2 can also be phosphorylated and inactivated by the 
activated Ras/extracellular signal-regulated kinase (ERK)/mitogen-activated protein 
kinase (MAPK) signaling pathway [19]. 
Another critical regulator of mTORC1 is the adenosine monophosphate-activated protein 
kinase (AMPK), which is activated when cellular energy level is low. AMP linking to 
AMPK allows its phosphorylation (while ATP availability prevents it) triggering 
repression of energy-consuming processes, also inhibiting mTOR, and enhancing energy-
producing processes. AMPK phosphorylates TSC2 in different sites than Akt, activating 
rather than inactivating TSC2, and phosphorylates Raptor, thus achieving mTORC1 
repression [23]. 
mTORC1 activation requires sufficient amino acid levels, though it is not clear how these 
levels are sensed. Amino acid regulation requires the formation of a Rag GTPase 
complex, which binds Raptor, in order to translocate mTORC1 to the lysosome allowing 
its association with Rheb, and thus its activation [24]. 
The activation of mTORC1 leads to several downstream effects, including protein 
synthesis promotion. Raptor binds to the eukaryotic translation initiation factor 4E- 
(eIF4E-) binding protein 1 (4E-BP1) and the ribosomal protein S6 kinase beta-1 (S6K1), 
recruiting them to the mTORC1 complex and allowing their phosphorylation [25, 26]. 
Hyperphosphorylation of 4E-BP1 by mTOR prevents the association of 4E-BP1 and 
eIF4E, allowing eIF4E to bind eIF4G to begin translation. Phosphorylation of S6Ks, 
including several S6K1 isoforms and S6K2, by mTOR promotes their activation and thus 
the phosphorylation of their targets involved in mRNA translation. S6K1 is also involved 
in negative feedback on mTORC1 and mTORC2 [27]. 
The mTORC1 complex and AMPK also regulate the autophagic process, a cellular 
mechanism through which cells eliminate damaged components associated with a wide 
range of diseases, including cancer. After glucose deprivation, AMPK associates with, 
and directly phosphorylates, the serine/threonine Unc-51-like autophagy activating kinase 
(ULK1), an upstream component of the autophagy mechanism. By contrast, when 
nutrients are plentiful, mTORC1 phosphorylates ULK1, preventing its association with 
and activation by AMPK, inhibiting autophagy [28]. 
Aberrant activation of the PI3K/Akt/mTOR pathway is often found in human cancers and 
promotes cell proliferation [29]. Activation has been shown in the lung, head, and neck 
and breast, gynaecologic, colorectal, and prostate cancers and glioblastoma multiforme 
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[30] and also in B-lineage acute lymphoblastic leukemia [31]. PI3Ks are pivotal 
molecules in this pathway and possess eight isoforms grouped into class I, class II, and 
class III. Class I PI3Ks (PI3Kα, β, γ, and δ), stimulated by Tyr kinases, G protein-coupled 
receptors, and Ras, are currently the focus of research in drug development. Mutation of 
the PIK3CA gene, which encodes the catalytic subunit α (p110α), one of the class I PI3K 
isoforms, is found in several cancers [32]. The signaling and biological roles of class II 
and III PI3Ks are not clear, and they have not been implicated in oncogenesis [32]. 
In TNBC, the activation of the PI3K/Akt/mTOR pathway is induced by an 
overexpression of upstream regulators (i.e., growth hormone receptors), mutations of the 
PIK3CA gene, and by decreased activity of the phosphatase and tensin homolog (PTEN) 
and of the proline-rich inositol polyphosphatase, which are downregulators of PI3K [33–
35]. By contrast, activation of downstream effectors of PI3K (e.g., Akt and mTOR) and 
activation of downstream effectors of parallel pathways (MAPK and Ras) are rare events 
in TNBC [36]. Furthermore, other oncogenic pathways (i.e., FGFR, cMET, and RAF) 
regulated by P53 inactivation converge to activate the PI3K pathway [37]. 
Due to the frequent activation of the PI3K/Akt/mTOR pathway in human cancers, more 
than 50 inhibiting drugs are in development, and several clinical trials are ongoing [38]. 
The first established therapeutic anticancer agents targeting this pathway are everolimus 
and temsirolimus, which abrogate mTOR signaling, and have been approved by the U.S. 
Food and Drug Administration. Based on the results obtained with everolimus in 
pancreatic neuroendocrine tumors [39], and temsirolimus for advanced renal cell cancer 
[40], these agents are now approved for treatment of these diseases. 
Therapies targeting other pathway members have been described. Monotherapy using 
pan-class I PI3K, which inhibits all class I PI3K isoforms, has effects at dose-limiting 
toxicity, leading to prolonged disease stabilization in some patients with advanced solid 
tumors (especially the lung) during phase I clinical trials [41]. Isoform-specific PI3K 
inhibitors have also been tested and have shown an antitumor activity in tumors such as 
p110δ- (isoform δ-) driven hematologic malignancies [42] or PIK3CA-mutant HR-
positive BC [43]. Akt inhibitors and mTORC1/2 inhibitors aimed to suppress not only 
mTORC1, but also the feedback activation of Akt by mTORC2 [44], are currently being 
investigated in clinical studies [45]. The use of PI3K/Akt/mTOR pathway inhibitors is 
often associated with MAPK inhibitors, growth factor receptor inhibitors, and endocrine 
18 
 
therapy. Furthermore, they might sensitize tumors to chemotherapy synergistically 
inducing apoptosis, as showed in sarcomas [46]. 
These promising strategies are now under investigation for the treatment of several 
tumors, including nonsmall cell lung cancer [47], colorectal cancer [48], nonmedullary 
thyroid carcinoma [49], and B-lineage acute lymphoblastic leukemia [31]. Although these 
strategies have been shown to be effective, there is great variability in the duration and 
quality of their benefits and the long-term side effects for patients. Thus, the 
identification of protein and/or genetic biomarkers to recognize subjects that will benefit 
the most from these therapeutic strategies is essential [50]. In TNBC, the development of 
PI3K/Akt/mTOR-targeted therapies, taking into account the inhibitors of this pathway 
alone or in combination with other strategies, will provide new tools to control disease 
progression and improve outcomes [51]. In a recent phase 2 clinical trial, the efficacy of 
ipatasertib (an Akt inhibitor) in association with paclitaxel (an antineoplastic agent used 
in TNBC treatment) was shown [52]. 
 
2.2. MicroRNAs and mTOR Signaling in BC 
Several studies highlight the role of circulating microRNAs (miRNAs), in different 
tumors, including BC and the TNBC subtype [16]. In particular, recent evidence has 
shown that miR10a is downregulated in triple-negative BC cells [53]. Furthermore, 
overexpression of miR-10a decreases the proliferation and migration of TNBC cell lines 
via PI3K/Akt/mTOR signaling and through the mitochondrial apoptotic pathway [53]. 
Recently, Phua et al. [54] demonstrated that miR-184 is also downregulated in TNBC 
patients and that miR-184 overexpression in TNBC cells leads to a reduced expression of 
mTOR. The decreased cancer cell proliferation, due to mTOR reduction, has been 
confirmed in vivo: mice injected with mir-184-transfected MDA-MB-231 cells showed a 
delayed primary tumor formation and reduced metastatic burden. Emerging evidence 
points to epigenetic silencing by hypermethylation as a possible mechanism through 
which these tumor suppressor/growth inhibitor miRNAs are downregulated in TNBC 
[55]. In metastatic breast tumors, miR-184 has been found to be hypermethylated 
compared to the methylation status of miR-184 in normal breast tissue, suggesting a 
selective pressure in silencing this miRNA during the metastatic process [54]. 
Upregulation of miR-21 was detected in TNBC tissues and in MDA-MB-468 cells by 
Fang et al. [56]. Inhibition of this miRNA resulted in decreased proliferation, viability, 
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and invasiveness of TNBC cells and enhanced apoptosis. Experiments to identify miR-21 
targets have shown that PTEN is downregulated, suggesting an activation of mTOR and 
the oncogenic properties of miR-21 in TNBC, with increased proliferation and invasion 
by TNBC cells. Another miRNA that has been found to be upregulated in TNBC tissues 
in comparison to non-TNBC or adjacent tissues is miR-146a. Indeed, it has been reported 
to be significantly related to tumor size and histological stage: patients with elevated 
miR-146a expression have lower survival rates and worse prognoses than low-expression 
individuals [57]. In addition, miR-146a has been shown to bind the 3-UTR region of 
BRCA1, inhibiting its expression; the BRCA1 protein is absent or present at very low 
levels in about one-third of sporadic BCs [58]. Evidence suggests that downregulation of 
BRCA1 expression leads to Akt/mTOR oncogenic pathway activation [59]. Hence, 
strategies that could modify the deregulated status of these miRNAs in TNBC could have 
a pivotal role in inhibiting the Akt/mTOR pathway and could affect TNBC initiation and 
progression. It is not yet known how these miRNAs might be modulated by exercise and 
whether they can be associated positively or negatively with TNBC progression, for 
which there are no reliable prognostic factors. 
 
2.3. Autophagy and mTOR Signaling 
Autophagy is the cellular mechanism responsible for the degradation of cytoplasmic 
components. It is through this mechanism that cells maintain cellular homeostasis by 
eliminating damaged proteins and organelles and by providing substrates for energy 
generation and biosynthesis under stress conditions. The mTOR complex is a major 
negative regulator of autophagy. It suppresses autophagy in response to nutrients, growth 
factors, and hormone availability, promoting protein synthesis, cell division, and 
metabolism. The mTOR signaling pathway is frequently activated in tumor cells, 
resulting in the activation of its growth-promoting functions and the inhibition of 
autophagy [60]. In cancer, the cytoprotective role of autophagy could prevent 
tumorigenic transformation by inhibiting chronic tissue damage. By contrast, once cancer 
occurs, cancerous cells could utilize autophagy to enhance fitness and survive in the 
hostile tumor microenvironment, providing energy via substrate degradation. Autophagy 
could therefore be tumor suppressive (for example, via elimination of damaged cellular 
components), as well as tumor promoting in established cancers [61]. In addition, 
autophagy has recently been shown to play a role in necroptosis, and, together with 
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apoptosis, autophagy also regulates other death pathways, including immunogenic cell 
death, entosis, and pyroptosis [62]. It has been demonstrated that suppression of 
autophagy in epidermal growth factor receptor- (EGFR-) driven nonsmall cell lung 
adenocarcinoma xenografts promotes cell proliferation, tumor growth, and 
dedifferentiation, as well as resistance to EGFR tyrosine kinase inhibitor therapy [63]. 
Moreover, autophagy suppresses early oncogenesis in lung adenocarcinoma through 
effects on regulatory T cells [64], and autophagy genes are often required for the 
cytotoxic effects of chemotherapy [65]. In view of the complex- and context-dependent 
role of autophagy in cancer progression and response to therapy, it could be hypothesized 
that the inhibition of the mTOR pathway and the consequent induction of autophagy may 
be useful in certain cancers through autophagy-dependent antitumor immunity, 
autophagy-dependent cytotoxic effects, or other tumor-suppressor effects [66]. In 
addition to its effects on skeletal muscle, exercise has also been found to induce 
autophagy in the liver, pancreas, adipose tissue, and cerebral cortex in transgenic mouse 
models [67, 68]. Whether exercise-induced stress activates autophagy in healthy cells (or 
cells primed for malignant transformation), or cancer cells themselves, and whether such 
effects inhibit or potentiate tumorigenesis, is not known and needs further investigation 
[15]. 
 
 
3. Evidence of mTOR Modulation by Exercise in TNBC 
 
3.1. mTOR and Exercise 
PA reduces mortality for all diseases, including tumors [69], reducing the incidence of 
primary development and ameliorating the prognosis [15]. Hence, it should be prescribed 
like a medication indicating the correct typology, dose, and timing, i.e., the type, 
intensity, duration, and frequency of exercise as described in Exercise Prescription in BC 
Survivors. Physiological adaptations to exercise occur not only in skeletal muscle but also 
systemically in other metabolically active tissues involved in the exercise response (such 
as the bone, heart, adipose, endothelium tissue, and brain) profoundly altering the 
systemic milieu, in turn influencing the tumor microenvironment and cancer hallmarks 
[15]. In order to understand the effect of PA on mTOR and BC, muscular, systemic, and 
microenvironment effects should be considered. 
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3.1.1. Aerobic Exercise and Muscular Effects 
In skeletal muscle, aerobic exercise activates several adaptive pathways, including 
protein kinases, transcription, and coregulatory factors that, by gene expression 
modification, increase mitochondrial biogenesis and stimulate metabolic reprogramming 
[70]. Exercise induces a depletion of nutrients, energetic substrates, and nicotinamide 
adenine dinucleotide (NAD)H that elevate the ratios of AMP : ATP and NAD+ : NADH, 
directly activating AMPK and other metabolic sensors, including NAD-dependent protein 
deacetylase sirtuin 1 (SIRT1) and kinases, such as ERK1/2, p38 MAPK, and Jun N-
terminal kinase (JNK) [71]. These energy sensors trigger the transcriptional regulator 
peroxisome proliferator-activated receptor-γ coactivator 1α (PGC1α), which regulates the 
expression of mitochondrial biogenesis, increase the expression of mitochondrial 
transcription factor A (TFAM), which, once transferred to the mitochondria, controls 
transcription of mitochondrial DNA [71]. Moreover, aerobic exercise, through PGC1α 
phosphorylation, influences other transcription factors, including peroxisome proliferator-
activated receptor-γ (PPARγ), an important regulator of fatty acid oxidation and estrogen-
related receptor-α (ERRα) and ERRγ, which directly regulate mitochondrial energy 
metabolism by oxidative phosphorylation, fatty acid oxidation, and the tricarboxylic acid 
(TCA) cycle [72,73]. In this regard, the reactive oxygen species (ROS) and reactive 
nitrogen species produced by exercise also directly or indirectly regulate contraction-
induced mitochondrial biogenesis [74] and skeletal muscle metabolic reprogramming via 
AMPK and PGC-1α [75]. AMPK-mediated cell survival requires inhibition of mTOR. 
Therefore, AMPK and mTOR play antagonistic roles in cells and inhibition of mTOR is 
essential for AMPK-mediated metabolic homeostasis [76]. 
 
3.1.2. Resistance Exercise and Muscular Effects 
In skeletal muscle, resistance exercise causes an increase in muscle size and strength via 
mTOR activation. In canonical growth factor signaling, mTOR is activated by PI3K/Akt, 
through IGF-1 and insulin signaling, but a considerable body of evidence suggests that 
mTORC1 is also likely activated by a growth factor-independent movement of proteins to 
and from the lysosome, via resistance exercise-induced phosphorylation of TSC2 [77]. 
Cellular trafficking of mTOR and its association with positive regulators that occur in 
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human skeletal muscle leading to protein synthesis after resistance exercise, in fed 
condition, were recently confirmed by Song and colleagues [78]. 
 
3.1.3. Systemic and Microenvironment Effects of Exercise 
Exercise stimulates the release of molecular signals such as muscle-derived regulatory 
RNAs, metabolites, and myokines with autocrine, paracrine effect on energetic substrate 
oxidation, hypertrophy, angiogenesis, inflammation, and regulation of the extracellular 
matrix. To better evaluate the systemic response to PA, a distinction must be drawn 
between long term (training) and acute exercise. Training induces a reduction of basal 
concentration of circulatory sex hormones and lowers adiposity, both recognized risk 
factors [79], while acute exercise causes a sharp increase in circulating hormones, 
cytokines, and immune cells [80–82]. Both the systemic adaptations to training and the 
strong response to acute exercise support plausible mechanisms that inhibit 
carcinogenesis by suppressing the activation of mTOR signaling network. Hence, 
exercise may improve BC outcomes [14] (Figure 1). Moreover, both long-term training 
and a single bout of exercise control energy availability and induce a hormetic response 
that accounts for the physiological cellular stress adaptation [83,84]. 
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Figure 1: In this figure, we consider potential mechanisms regulated by physical activity and 
caloric restriction in inhibiting the mTOR pathway. Both refer to energy availability inhibiting 
carcinogenesis by suppressing the activation of the mTOR signaling network in this subtype of 
mammary carcinoma. The mTOR inhibition is mediated through the effects of vigorous PA or 
long-term exercise on systemic response such as concentrations of the circulating growth factors 
and hormones (i.e., IGF-1 and insulin) that regulate the mTOR network. The network is 
controlled through the PI3K/Akt signaling pathway, the glycaemia and glutamine levels, inducing 
apoptosis and reversing malignancy-associated metabolic programming. Moreover, the control of 
energy availability by both exercise and CR induces a mitohormetic response that accounts for a 
physiological cellular stress adaptation through AMPK activation inducing mTOR inhibition. In 
this context, exercise should be considered in terms of its four components: frequency, intensity, 
time, and type; however, dose-dependent effects of each component on cancer protection via 
mTOR inhibition have not yet been clarified. Most data indicate that vigorous PA, either long-
term or in adulthood, may reduce a woman’s risk of mammarian cancer, especially TNBC 
relapse. The inhibition of the mTOR complex and its cell growth-promoting functions leads to a 
reduction of cell proliferation, control of cancer progression, and consequent autophagy induction 
probably involved in tumorigenesis prevention. Thus, we hypothesized that the exercise-induced 
inhibition of the mTOR pathway may be useful in the control of cancer progression, including 
TNBC. PA: physical activity; CR: caloric restriction; CHOs: carbohydrates; mTOR: mammalian 
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target of rapamycin; IGF-1: insulin-like growth factor 1; IGF-1R: insulin-like growth factor 
receptor 1; IR: insulin receptor; IGFBPs: insulin-like growth factor binding proteins; PI3K: 
phosphatidylinositol-3-kinase; AMPK: adenosine monophosphate-activated protein kinase; 
TNBC: triple-negative breast cancer. FITT-VP principle, which reflects the frequency (F), 
intensity (I), time (T), and type (T) of exercise, and its volume (V) and progression (P) over time, 
in an individualized exercise training program. 
 
 
Hormesis is a process whereby exposure to a low dose of a potential stress favours 
adaptive changes in the cell that enables it to better tolerate subsequent stress [85,86]. 
This type of stress is often related to reactive oxygen species (ROS) originating from the 
mitochondrial respiratory chain [87]. The accumulation of transient low doses of ROS 
through exercise influences signaling from the mitochondrial compartment to the cell 
[88]. Remarkably, this coordinated response to mild mitochondrial stress appears to 
induce mitochondrial metabolism, increase stress resistance, stimulate various long-
lasting cytoprotective pathways, and favour the establishment of an oxidant-resistant 
phenotype, hence preventing oxidative damage and chronic diseases. Accordingly, low 
levels of ROS elicit positive effects on physiological cellular and systemic responses and 
ultimately increase lifespan [83,88–93]. The hormetic nature of exercise, which produces 
low levels of ROS, emerges as a key feature for cancer control. Indeed, in the tumor 
microenvironment, the activation of exercise-induced hormesis of the AMPK-p38-PGC1-
α axis supports oxidative metabolism maintaining the cellular ATP pool and conserving 
cellular energy and viability during the metabolic stress condition: AMPK regulates 
metabolism and energy homeostasis [94,95]. Exercise-induced mitochondrial biogenesis 
improves mitochondrial function in addition to the upregulation of antioxidant defenses 
that function as back regulators of intracellular ROS levels, and leads to improved redox 
homeostasis [96,97] as well as significantly improved insulin sensitivity. By contrast, 
high levels of ROS cause functional oxidative damage to proteins, lipids, nucleic acids, 
and cell components, induce a significant increase in intracellular Ca
2+
, and promote 
signaling cascades for apoptosis or autophagy via NF-κB or forkhead box sub group O 
(FoxO) pathways. High ROS levels are therefore reputed to act as etiological, or at least 
exacerbating factors in chronic/aging-related diseases. 
The typical hormetic response modulated by exercise involves kinases, deacetylases, and 
transcription factors; many of which have also been shown to be involved in the 
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carcinogenic process [86]. The most studied are sirtuins (SIRT), which are histone 
deacetylases, and the FoxO family of transcription factors. The pathways in which NF-
kappaB and the Nrf-2/ARE are components are also involved in hormetic responses and 
implicated in carcinogenesis and are modulated by exercise [86]. 
FoxO transcription factors play a critical role in cell cycle control and cellular stress 
responses. FoxOs are known to be regulated by the insulin signaling pathway; however, 
recently, the research group of Burnet demonstrated that AMPK phosphorylates 6 
specific residues on FoxO and opposes the phosphorylation of other FoxO sites by Akt 
[98]. Phosphorylation of FoxO by AMPK affects the conformation of the protein in such 
a way that sirtuin-mediated deacetylation is also modified [99]. The dependence of 
sirtuins on nicotinamide adenine dinucleotide (NAD(+)) links their activity to cellular 
metabolic status. Emerging evidence indicates that deacetylation of FoxO by SIRT1 
favours expression of cell survival/stress resistance and the downregulation of 
proapoptotic genes [85,100,101]. Sirtuins therefore protect against cancer development as 
they regulate the cellular stress responses and ensure that damaged DNA is not 
propagated and that mutations do not accumulate [99]. However, how FoxO activation is 
influenced by exercise remains unclear. In addition, cytokines such as those that we and 
others have found to be regulated by exercise and training [14,102–104] have been 
reported to have direct and indirect effects on cellular stress responses modulated by 
acetylation/deacetylation reactions, and these effects can be further modified by cortical 
steroids, which exercise dramatically induces [105]. 
Similarly, various chemical mimetics of PA and caloric restriction (CR) such as AICAR, 
PPARδ agonist, resveratrol, and metformin can trigger a beneficial response by activation 
of key regulators of stress tolerance at the level of transcription, posttranscriptional 
modifications, and regulation of energy metabolism [92,106]. Cross talk between major 
CR hormesis-induced pathways, especially AMPK/PPAR and antioxidant systems, IGF-
1, and homeostatic energy balance, reveals the correlation between CR and exercise 
mimetics [107]. 
Likewise, depending on the exercise, the level/persistence could induce an adaptive 
response that might turn the same process from “physiologic” into “pathologic,” as in the 
case of inflammation. Careful titration of ROS levels within specific tumor 
microenvironments may lie at the crossroads between the prevention, protection, and/or 
initiation and progression of disease, in particular, as regards the induction of 
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mitochondrial functionality, cellular homeostasis, and more generally, cellular metabolic 
health. 
Considering the type of exercise, both aerobic and resistance training increase glucose 
uptake in skeletal muscle via insulin-independent mechanisms, with a subsequent 
decrease in circulating levels of insulin, IGF-1, and glucose [108]. In a model of 
mammary carcinogenesis, PA caused a delay in carcinogenesis with a concomitant 
activation of AMPK and reduction in Akt and mTOR activation and reduction in insulin 
and IGF-1 in circulation [12]. Reduction of insulin levels is an important aspect given 
that hyperinsulinemia and insulin resistance are commonly observed in obesity with 
adipokine alterations, conditions associated with increased risk of BC and poor prognosis 
[8]. Insulin resistance is a condition in which the target tissues of insulin such as skeletal 
muscle, adipose tissue, and liver show a reduction in their response to physiological 
concentrations of the insulin hormone. As a consequence, the pancreatic β-cells produce 
more of the hormone to compensate for the defective response of target tissues, thus 
leading to hyperinsulinemia. BC cells express high levels of the insulin receptor (IR), and 
increased circulating insulin is associated with BC recurrence and death [109]. In 
contrast, PA has a fundamental role in reducing muscle insulin resistance and 
normalizing circulating insulin levels. Regular exercise in both healthy and oncological 
conditions ameliorates glycemic control including glycated hemoglobin (HbA1c) and 
insulin sensitivity in a “dose”-dependent manner according to duration and intensity 
[110,111]. Skeletal muscle in virtue of its mass and high rate of insulin and exercise-
stimulated glucose transport, represents the most important tissue in glucose uptake. 
Exercise per se increases trafficking of glucose transporter 4 (GLUT4) to the plasma 
membrane through insulin-independent mechanisms [112]. Under normal physiological 
conditions, in skeletal muscle, insulin actions are mediated by the IR-catalyzed 
phosphorylation of the IR substrates 1 and 2 (IRS1 and IRS2). The tyrosine-
phosphorylated IRS proteins then interact with and activate PI3K, a critical player in 
insulin signaling, particularly with regard to glucose homeostasis. Activation of PI3K 
generates PIP3 that induces membrane translocation of the serine/threonine kinase Akt. 
PIP3 activation of PDK1 and the Rictor/mTOR complex 2 leads to phosphorylation and 
subsequent activation of Akt [113]. Akt phosphorylates TBC1D4 (also known as Akt 
substrate of 160 kDa, AS160) and TBC1D1 promoting the translocation of GLUT4 
vesicles from intracellular compartments to membrane for glucose uptake [114]. 
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Although recent findings help to better understand the effect of exercise on glycemic 
control, the specific exercise-induced signaling mechanisms leading to the acute and 
long-term adaptations favouring enhanced glycemic control are less clear [112,115]. 
Endurance and, to a lesser extent, resistance exercise represent a significant metabolic 
stress, activating AMPK and thus inhibiting mTOR also in nonmuscular tissue such as 
liver, fat, and tumor tissues. In order to better evaluate the impact of exercise on mTOR 
in the BC microenvironment, not only AMPK, but also other circulating factors, should 
be considered. IGF-1, as well as insulin, activates the MAPK pathway and the PI3K 
pathway, which are both involved in cancer development and progression. The 
importance of IGF-1 axis in the development and progression of BC has been clearly 
shown [116]. The overexpression of IGF-1R in BC has been reported and related to 
poorer survival rates [117]. 
The IGF signaling system is composed by IGF-1 and IGF-2, insulin-like growth factor 
binding proteins (IGFBPs), a family of binding proteins regulating IGF half-lives and 
available in circulation and extracellular fluids, IGF receptors, and insulin receptors. 
Furthermore, we recently evaluated the complexity of the IGF-1 gene [118] and the 
biological activity of IGF-1 isoforms in BC cell lines [119] showing that the IGF-1 
isoforms induced cell proliferation via IGF1R phosphorylation. Some studies have 
reported conflicting results regarding the regulation of IGF-1. Such studies report an 
increase, no difference or a decrease in circulating IGF-1 levels associated with PA [120–
123]. These results are not surprising because the IGF-1 levels are influenced by several 
clinical factors such as gender, age, body mass index (BMI), sex steroid concentrations, 
nutrition, stress, level of PA, and intervening illness. Thus, exercise prescription should 
take into consideration most of these variables. 
Another process through which exercise might regulate tumor metabolism is the 
autophagic machinery [15], as described in Autophagy and mTOR Signaling. 
It is clear that exercise can ameliorate the BC microenvironment and can be very 
important in reducing BC risk and tumor burden when canonical radiochemotherapies or 
chemical mTOR inhibitors are not working, as in TNBC. Exercise workouts for these 
subjects will be explained in Exercise Prescription in BC Survivors. Ex vivo experimental 
data, using TNBC cell lines stimulated with sera collected before and after a single 
aerobic exercise bout (pre- or postexercise serum/a), are described in Experimental 
Evidence of mTOR Inhibition. 
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3.2. Experimental Evidence of mTOR Inhibition 
As regards the mechanisms involved in the exercise-induced reduction of TNBC risk and 
tumorigenesis, few data are available. Ex vivo experiments, working with TNBC cells 
stimulated with sera collected before and after a single aerobic exercise bout (pre- or 
postexercise serum/a), are a good starting point to understand how exercise could affect 
the progression and recrudescence of TNBC. The research group of Dethlefsen has 
demonstrated that incubation of MCF-7 estrogen-responsive BC cells and MDA-MB-231 
TNBC cells treated with postexercise serum, from both healthy volunteers [124] and 
operated cancer patients [14,124], resulted in a reduction of BC cell viability in 
comparison with BC cells incubated with preexercise sera. In particular, it has been 
demonstrated that MCF-7 and MDA-MB-231 stimulation with sera leads to a viability 
reduction of 11% in MCF-7 cells and 9% in MDA-MB-231 cells in the case of 
supplementation with postexercise serum from operated cancer patients receiving 
adjuvant chemotherapy compared to preexercise serum [124]. Furthermore, the viability 
of both BC cell lines supplemented with sera from healthy women was also significantly 
reduced by the exercise-conditioned sera, resulting in a 10% and 19% reduction in MCF-
7 viability and a 14% and 13% reduction in MDA-MB-231 viability by 1 h and 2 h 
postexercise sera, respectively. The reduced viability of MDA-MB-231 supplemented 
with 5% of healthy women 2-hour postexercise serum has also been confirmed by a pilot 
study that we performed working with culture medium with a physiological concentration 
of glucose (80mg/dl), resulting in a statistically significant reduction in cell proliferation 
of about 10% compared to cells supplemented with preexercise human serum [103]. 
Promising data on the tumorigenic potential of cancer cells in mice are also available. As 
reported by Dethlefsen et al. in 2017 [124], different outcomes in incidence and growth 
of tumors were detected inoculating NMRI-Foxn1nu mice with MCF-7 or MDA-MB-231 
BC cells preincubated for 48 hours with pre or postexercise sera from healthy volunteers. 
In particular, only 45% of the mice inoculated with MCF-7 supplemented with 
postexercise human serum formed tumors compared with 90% of mice inoculated with 
MCF-7 preincubated with at rest sera, and the volume of tumors was reduced by 76%. 
Moreover, tumor incidence in mice inoculated with MDA-MB-231 cells preincubated 
with postexercise sera tended to be lower than it was in mice inoculated with MDA-MB-
231 cells preincubated with rest sera, but no difference in tumor volume was observed 
between the two groups. These results show that exercise-stimulated changes suppress 
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BC cell proliferation and reduce the tumorigenic potential of BC cells, also in the case of 
TNBC cells. Another important aspect to be considered is the fact that PA has been 
reported to lead to an increased level of the catecholamines epinephrine (EPI) and 
norepinephrine (NE) [82]; this result has also been confirmed in BC survivors two hours 
after a single exercise session [124]. Moreover, by blocking the β-adrenergic signaling 
pathway in BC cells, the effects of postexercise sera in BC cell viability is completely 
blunted, indicating the crucial role of catecholamines in inhibiting BC cells viability and 
tumor growth [124]. Their role in exercise-induced effects on BC cell viability has also 
been confirmed by MCF-7 and MDA-MB-231 treatment with different doses of EPI and 
NE, resulting in a dose-dependent growth inhibitory effect in both BC cell lines. 
Catecholamines have been shown to induce a dose-dependent phosphorylation of yes-
associated protein (YAP) in MDA-MB-231 cells [125]; YAP is the main downstream 
target of the mammalian Hippo pathway and, when phosphorylated, it is retained in the 
cytoplasm. Hippo pathway is a tumor suppressor signaling cascade that regulates cell 
growth, and it has been shown to be a dysregulated pathway in several types of cancers, 
including BC, in which there is an activation of YAP oncoproteins and transcriptional 
coactivators with the PDZ-binding motif (TAZ) associated with tumor formation, growth 
and progression, metastasis, and drug resistance [126]. Dethlefsen et al. showed that the 
Hippo pathway is regulated by exercise-conditioned sera: incubation of BC cells with 
postexercise sera led to a time-dependent phosphorylation of YAP in MCF-7 BC cells 
and to a decreased expression of YAP target genes, due to phosphorylated-YAP 
cytoplasmic retention, in both MCF-7 BC cells and MDA-MB-231 TNBC cells [124]. 
Studies performed by Tumaneng et al. demonstrated that Hippo pathway is related to the 
mTOR signaling cascade: YAP mediates the effects of the Hippo pathway regulating 
target genes, including the miR-29; this miRNA family has been proven to inhibit PTEN, 
an upstream activator of mTOR [127]. In summary, the Hippo pathway can be activated 
by exercise through the production of the catecholamines EPI and NE and can inhibit BC 
cell growth through the action of YAP and miR-29, inactivating the mTOR pathway. 
As mentioned above, several miRNAs have been found to be deregulated in TNBC cells 
and patients; evidence suggests that different types of exercise can regulate these 
miRNAs in different ways. One of these miRNAs is miR-21, which has been found to be 
upregulated in TNBC patients; it has an oncogene activity and plays a crucial role in 
tumor cell proliferation and invasion, repressing PTEN [128]. 
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Nielsen et al. [129] showed how miR-21 level significantly decreased 3–5 days after 
endurance training (60 min of cycle ergometer exercise at 65% of Pmax, 5 times a week 
for 12 weeks), at rest. However, levels of miR-21 were also found to be upregulated 
immediately after a single exhausting cycling exercise at a low heart rate, just as it was 
after a training period of 90 days [130]. Discrepancies between data obtained by these 
two studies could be explained by the different types of exercise considered, as confirmed 
by Wardle et al. [131]. 
The microRNA precursor miR-146a has also been found to be an upregulated miRNA in 
TNBC tissues, and its level is related to tumor size and survival rate. Nielsen et al. [129] 
showed that miR-146a levels significantly decreased immediately after a single session of 
pedaling exercise performed at 65% of the maximal power output. In this case, depending 
on the different exercise considered, miR-146 levels can be dysregulated: after a single 
exhausting cycling exercise at a low heart rate, it has been found to be upregulated [130]. 
Variations in miR-146 levels when comparing strength or endurance exercise groups to 
controls were observed; levels increase in the endurance group, while they decrease in the 
strength group [131]. The downregulation of miR-146a after strength exercise was also 
confirmed by a study that involved a single strength exercise session performed at 70% of 
one-repetition maximum [132] in which the miR-146a level was found to have decreased 
3 days after exercise. 
In short, a subset of circulating miRNAs, including miR-21 and miR-146a, are associated 
with the whole-body adaptive response to differential forms of exercise and training. 
These miRNAs have been found to be upregulated in TNBC patients and related to the 
repression of PTEN or BRCA1 with consequent mTOR pathway activation. Hence, their 
downregulation with specific types of exercises could be a very promising approach to 
control TNBC initiation and progression. 
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4. Energy Intake in TNBC and mTOR Modulation 
 
mTORC1 is a key regulator of cell growth and proliferation, and at the same time, it is 
also at the centre of nutrient regulation and utilization. In this regard, a large number of 
studies have demonstrated the role of excessive energy intake on cancer development, 
and by contrast, the protective effects of CR [133]. While the antitumorigenic effects of 
CR are well established, the mechanism behind this relationship is not completely clear, 
though it is believed that the tumor suppressive effects are mediated, as they are for 
exercise, by enhanced apoptosis, modulation of systemic signals such as IGF-1, insulin, 
metabolic, and inflammatory pathways, as well as by reduced angiogenesis [134]. 
Specifically, a large quantity of data points to the role of mTOR activation in cancer 
development through protein-induced IGF-1 signaling and to the beneficial effects of 
caloric and protein restriction not only on aging-associated diseases such as cancer but 
also on life span [135,136] (Figure 1). 
CR increases the level of the circulating adiponectin, which can exert anticancer effects 
through mechanisms that include an increase in insulin sensitivity, a decrease in 
insulin/IGF-1 and mTOR signaling via AMPK activation as well as a reduction in the 
proinflammatory cytokine expression via inhibition of the nuclear factor κ-light-chain-
enhancer of activated B-cells (NF-κB) [136,137]. 
AMPK, as mentioned above, is an important mediator in the maintenance of cellular 
energy homeostasis, and recently, it has gained attention for its possible role as a 
metabolic tumor suppressor and in cancer prevention and control. Since AMPK 
phosphorylation is regulated by energy availability (AMP : ATP ratio), AMPK activators, 
such as metformin, CR, and aerobic exercise, reduce the incidence of cancer. 
Leptin is a peptide hormone produced by white adipose tissue. It affects several tissues 
and acts on the hypothalamus to regulate appetite and energy expenditure. It also impacts 
carcinogenesis, angiogenesis, immune responses, cytokine production, and other 
biological processes [138,139]. 
Intermittent CR is associated with the suppression of murine mammary tumor incidence 
and a decrease in the leptin-to-adiponectin ratio [139]. This ratio, when elevated, is 
related to metabolic syndrome and some cancers [140,141]. In TNBC metastases, CR 
decreases proliferation, increases apoptosis, and downregulates the IGF1-1R pathway, 
coadiuvating canonical therapies [142]. Taken together, these findings show that dietary 
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interventions can ameliorate the systemic milieu and tumor microenvironment. Chronic 
CR is not suitable for cancer patients at risk for weight loss, cachexia, and 
immunosuppression, but it can be substituted with intermittent CR, fasting-mimicking 
diets, low carbohydrate/ketogenic diets, or CR mimetic drugs. 
Fasting and low carbohydrate diets have been shown to reduce side effects and to 
enhance the effectiveness of chemotherapy and radiation therapy in animal models, and 
there is a great deal of interest in the potential clinical value of these interventions. 
Protein consumption has different effects on cancer mortality, which vary according to 
age, with an increased risk in middle age and a reduction in the elderly [143]. 
Protein restriction (PC) for the middle-aged followed by moderate protein intake in 
elderly subjects may increase longevity and health span since protein restriction is 
sufficient to reduce growth hormone receptor (GHR)-IGF1 activity and can reduce cancer 
incidence in model organisms regardless of energy intake [144]. 
Moreover, L-type amino acid transporter 1 (LAT1), which transports large quantities of 
neutral amino acids, was found highly expressed in human BC tissues. The upregulation 
of LAT1 plays an important role in BC progression because more amino acids are 
required for protein synthesis and cellular proliferation [145]. 
The activation of the mTOR/S6K1 signaling pathway depends on the availability of 
amino acids (AA), particularly branched chain AA, such as leucine, and also glucose 
[106]. Growth factor signals, which usually activate mTORC1 signaling, have little or no 
impact in the absence of AA. 
Leucine deprivation causes an upregulation of insulin-like growth factor binding protein 
1 through transcriptional activation and mRNA stabilization, probably decreasing the 
effects of IGF1 and thus lowering cell proliferation [146]. 
However, in most BC cell lines with constitutively activated Akt/mTOR signaling, 
leucine restriction is not efficient in inhibiting mTOR signaling since it is associated with 
activation of survival molecule Akt, making leucine deprivation an undesirable approach 
for BC therapy [146]. 
Glutamine is another AA involved in the regulation of the mTOR pathway inducing the 
uptake of leucine [147]. Tumor cells are more sensitive to amino acid deprivation than 
normal cells; thus, glutamine restriction and/or transporter inhibition decrease mTOR 
activity [147]. 
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A novel therapeutic approach based on whey protein concentrate (WPC) supplementation 
for BC treatment has been suggested by Cheng et al. [148]. WPC is rich in bioavailable 
cysteine, which can be used for glutathione synthesis, and contains all nine essential AAs. 
WPC promotes muscle protein synthesis [149] and can be used as a nutritional 
supplement during chemotherapy [150]. WPC has also been shown to enhance rapamycin 
sensitivity in MDA-MB-231 TNBC cells, a cell line resistant to rapamycin and other 
mTOR inhibitors [148]. 
The combination of conventional therapies and n-3 polyunsaturated fatty acid (PUFA) 
supplementation (nutritional interventions) increases the sensitivity of tumor cells to 
conventional therapies, possibly improving their efficacy especially against cancers 
resistant to treatment, as suggested by D’Eliseo and Velotti [151]. Eicosapentaenoic acid 
(EPA) and docosahexaenoic acid (DHA) have anticancer effects on different cancer types 
by inducing apoptotic cell death in human cancer cells either alone or in combination 
with canonical therapies. EPA and/or DHA also have proapoptotic effects in both triple-
negative [152] and ER+ BC subtypes [153], although when compared at the same dose, 
DHA appears to be more effective. This might be due to the structural differences 
between DHA and EPA. The proapoptotic effects occur with increases in plasma 
membrane incorporation and decreases in cell viability [152–154], PI3K/Akt pathway 
[155], and pEGFR activation [152]. 
In agreement, CR and other nutritional interventions could play an important role in 
support of conventional therapies to improve TNBC outcomes. 
 
 
5. Exercise Prescription in BC Survivors 
 
In general, reviews and meta-analyses tend to group PA and exercise interventions into 
general categories and rarely examine the specific exercise protocols employed in the 
studies. Therefore, which characteristics make an exercise protocol safe and effective for 
BC survivors and, particularly, for TNBC patients? 
Since the 2009 roundtable consensus statement on exercise guidelines for cancer 
survivors [156], which outlined the situations in which deviations from the 2008 US 
Physical Activity Guidelines for Americans (PAGA) were appropriate and included 
relevant implementation strategies [157], exercise recommendations from several 
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internationally recognized institutions, such as the American Cancer Society [158] and 
the National Comprehensive Cancer Network [159], have been published for BC 
survivors. Fortunately, all of the abovementioned publications have recently been 
reviewed within the framework for exercise prescription of the American College of 
Sports Medicine (ACSM) [160], along with others providing practical guidance for 
exercise prescription in these patients [161,162]. ACSM’s framework for exercise 
prescription employs the so-called FITT-VP principle [160], which considers the 
frequency (F), intensity (I), time (T), and type (T) of exercise and its volume (V) and 
progression (P) over time in an individualized exercise training program. 
A detailed description of the FITT-VP principle for each type of exercise—i.e., aerobic, 
resistance, and flexibility—adapted to BCS needs is provided in Tables 1, 2, and 3. Note 
that the following guidelines should not be regarded as specific for BC patients because 
no studies, to date [163], have adopted (and/or reported) the proper application of the 
principles of specificity, progression, overload, initial values, and adherence, within their 
exercise interventions. Therefore, although specific exercise guidelines for cancer 
survivors still need to be outlined, particularly for TNBC survivors, the following 
information represents the most up-to-date adaptations of the PAGA to BCS, including 
TBNC patients. Improving the reporting of exercise prescriptions will also allow for more 
specific recommendations regarding types and doses of exercise for BCS (and, hopefully, 
for the TNBC subgroup), in order to identify effective exercise interventions to be 
delivered to this growing community. 
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6. Benefits of Exercise Pre- and Postdiagnoses 
 
Humans have not been “designed” for a sedentary lifestyle. The absence of an adequate 
level of PA puts us at increased risk of developing cancer. This has been highlighted by 
the European Breast Cancer Conference [164], issued an important statement: regular PA 
reduces the risk of BC for woman of any age and body weight by 12%. 
PA as a nonpharmacological treatment to combat the collateral effects associated with 
BC is under considerable scientific attention [160,165,166]. To allow physicians to 
prescribe PA to patients before and after treatment, scientific clarity and evidence 
supporting the thesis that PA programs reduce the damaging effects of cancer and its 
treatment are needed. Very little is known about the effect of exercise on TNBC 
outcomes, but data suggest that pre- and postdiagnosis PA may be one of the factors, 
which, if appropriately prescribed, could bring benefits to patients. 
Generally, TNBC has poor treatment outcomes because of a lack of receptor targets for 
conventional drugs to act upon. However, there is irrefutable evidence of the 
effectiveness of regular PA in primary and secondary prevention of premature death from 
any cause, including BC. Thus, different types of exercise can influence the prevention 
and progression of disease through several common mechanisms such as reduction of 
insulin resistance and improvement in immunity and cardiovascular function. Research in 
humans shows that exercise can regulate inflammation [13,167], oxidation [168,169], and 
gene expression [170]. 
Together with the potential mechanisms underlying the effects of exercise on breast 
carcinogenesis, Thompson [12] proposed three interesting hypotheses: (i) the hormesis 
hypothesis: oncological response to exercise is antithetical to a physiological cellular 
stress response; (ii) the metabolic reprogramming hypothesis: exercise reduces the 
glucose and glutamine available to mammary carcinomas, inducing apoptosis and 
reversing tumor-associated metabolic program; and (iii) the mTOR network hypothesis: 
exercise inhibits carcinogenesis by suppressing the activation of the mTOR signaling 
network in mammary carcinomas. 
Recent investigations have revealed that the most active women had, on average, a 25–
30% lower BC risk than women in the lowest category of recreational PA [171]. Data 
from the California Teachers Study (CTS) suggest that PA has a protective role in 
prediagnoses and may reduce a woman’s risk of BC, especially the TNBC subtype. An 
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analysis of the risk index (HR) associated with variations in the amount of PA hours 
among TNBC women yielded significant results. The HR results show significant 
associations when moderate-intense activity is considered as the only variable. When 
they are considered as separate variables, there are no statistically significant associations 
between moderate activity and TNBC, whereas intense activity is inversely associated 
with TNBC [172]. The reduction risk associated with baseline strenuous recreational PA 
was statistically significant among overweight or obese pre- or postmenopausal women, 
but not among their leaner counterparts. 
In patients with BC postdiagnosis, acute and chronic symptoms, such as muscle mass 
loss, fatigue, weight gain, hormone alterations, bone loss, cachexia, and adverse 
psychological effects, may all be favourably influenced by regular exercise. A 
prospective cohort study analysed modifiable lifestyle factors, including exercise, 
associated with total mortality and recurrence/disease-specific mortality in patients with 
TNBC [173]. The association between TNBC prognoses and exercise postdiagnosis 
yielded important results: women who engaged in exercise regularly during the first 6 
months postdiagnosis had a lower risk of total mortality and recurrence/disease-specific 
mortality, with adjusted HRs of 0.58 and 0.54, respectively. In addition, those who 
engaged in PA for a long time (2.5 h/wk) or women who exercised ≥7.6 metabolic 
equivalent hours/wk had a reduced risk of all causes and recurrence/disease-specific 
mortality compared with nonexercisers. Survivors who maintain a healthy weight and 
stay physically active have a better response to treatment and better survival outcomes. 
Thus, it is necessary to identify an appropriate promotion and prescription of regular PA 
for BC survivors in order to improve their prognosis, response to therapy, and quality of 
life. As previously described, the mTOR signaling pathway is differentially regulated by 
different exercise modalities, and it represents one of the main key regulators of the 
protective effects of exercise. 
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7. Conclusions 
 
In this review, we presented new insights into the downregulation of mTOR signaling in 
TNBC by exercise and CR. It has been shown that mTOR network inhibition is mostly 
mediated through the effects of CR and vigorous PA as well as long-term exercise, which 
decrease the level of circulating growth factors and hormones. 
During exercise, the body is exposed to different types of stressors, including 
temperature, metabolism, hypoxic, oxidative, and mechanical stress. These stressors 
initiate biochemical targets, which in turn actuate different signaling pathways that 
regulate gene expression and adaptive responses. Beneficial adaptation likely depends on 
the basal state of oxidative stress and inflammation at the beginning of exercise training. 
In turn, this basal state may depend on the periodization of training and recovery, 
together with age, health status, and diet. 
Exercise, as a hormetic agent, has the potential for beneficial energy upregulation. The 
dose response effects are complex and reflect activation of major defensive pathways in 
both systemic and local environments. A mitohormetic stimulus that occurs through a 
physiological cellular stress adaptation and AMPK activation across hormetic control 
circuits, such as increase of oxidative metabolism, mitochondrial biogenesis, 
angiogenesis, immune regulation and a decrease in BMI, and insulin secretion, are 
induced by exercise. Moreover, PA increases glucagon, catecholamines, and other 
hormones and influences miRNAs involved in cancer. Exercise as well as CR limit 
glycaemia and glutamine availability to mammary carcinomas, inducing apoptosis and 
reversing malignancy-associated metabolic programming. It is also known that 
intratumoral metabolism is regulated by exercise, but how this affects tumor growth and 
metastatic rate is not clearly understood. Although the signal for these hormonal and 
autonomic changes has been partially described in ex vivo experiments, such changes are 
difficult to transfer in vivo. Currently, there is an agreement in the literature that there is a 
role for exercise as a coadiuvant “medicine” in canonical therapies and that it has an 
increasingly protective tumorigenic effect. In this context, PA needs to be broken down 
into its main components: frequency, intensity, time, and type; however, the dose-
dependent effects of each of these components on cancer protection via mTOR inhibition 
are still unclear. Most data suggest that both vigorous and long-term PA in adulthood 
may reduce a woman’s risk of mammalian cancer, especially the TNBC subtype. 
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Finally, we can assert that there is a sufficient evidence showing that sedentary behaviour 
and nutritional risk factors for TNBC are modifiable. Hence, the suggestions regarding 
the modification of such risk factors highlighted in this review could have wide-ranging 
implications for society and may improve public healthcare cancer management. 
Accordingly, we would like to emphasize the importance of promoting physically active 
lifestyles to reduce the risk of relapse in TNBC. Fostering active lifestyles can provide 
important support during conventional cancer treatment, preventing the potential negative 
impacts on patients’ physical condition, as well as their emotional and social well-being. 
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Effects of exercise on triple-negative breast cancer cell proliferation 
 
Natalucci V. et al. 
 
Department of Biomolecular Sciences, University of Urbino Carlo Bo, Urbino, Italy 
 
Abstract 
 
Purpose: The purpose of this study was to examine if systemic responses to acute 
endurance exercise before and after 9 weeks of training in sedentary healthy women 
could modulate TNBC cell proliferation in vitro. 
Methods: Twelve healthy sedentary women (age: 21 ± 0.8 years, body height: 160 ± 4.7 
m, body mass: 53 ± 5.2 kg, BMI: 21 ± 1.2 kg/m
2
) performed 36 indoor cycling training 
sessions over a 9-week period. Before (pre) and after (post) this training protocol, 
subjects were asked to perform a High-Intensity Endurance Cycling (HIEC) test. The 
HIEC Test consists of a 20 minutes warm-up composed of four 5 minutes steps at 50%, 
60%, 65% and 70% of individual maximal power (Pmax), previously determined by an 
incremental test. After the warm-up, subjects performed ten 90 seconds. Sprints (“SPR” 
steps) at 90% Pmax separated by 3 minutes recovery intervals (“REC” steps) at 55% 
Pmax. At the end of the last REC step, subjects performed an eleventh SPR step to 
exhaustion. Blood samples were collected before, immediately after, and 4 h and 24 h 
post-HIEC Test and creatine kinase (CK) was determined to evaluate muscle adaptation 
response to exercise. The sera obtained were used to supplement a culture medium for 
TNBC MDA-MB-231 cells to evaluate cell proliferation. TNBC cells were seeded at 
20.000 cells/well in 24-well plates. After overnight incubation, the culture medium was 
replaced with DMEM red-phenol free with a physiological concentration of glucose (0.8 
mg/mL) and 5% conditioned human serum collected pre- or post- exercise. After 48 
hours, the cells were counted by trypan blue exclusion assay using a hemocytometer. 
Results: Sera collected after acute endurance exercise performed pre- and post-training 
induced the same effect on TNBC cell proliferation. In particular, 4 h post-exercise 
serum, both pre- and post-training, led to a statistically significant reduction in 
proliferation of about 24-25% compared to cells supplemented with pre-exercise serum 
(one-way ANOVA followed by Dunnett's Multiple Comparison Test; p<0.001). The 
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reduction in proliferation found in 4 h post-exercise serum was also maintained in 24 h 
post-exercise serum. Furthermore, we observed an increase of CK level in blood after 
HIEC exercise session in both pre- and post-training. However, trained women showed a 
lower level of CK 24 h post-exercise and a faster recovery of muscle response to physical 
activity. 
Conclusions: The systemic responses induced by a high-intensity endurance cycling 
session, pre- and post-training, might reduce cancer cell proliferation. 
 
 
Keywords 
Exercise, high-intensity endurance cycling; triple-negative breast cancer  
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1. Introduction 
 
About 10-20% of breast cancers (BC) are found to be triple-negative (TNBC). TNBC is  
characterized by the absence of estrogen receptors (ER) and progesterone receptors (PR), 
and does not show an overexpression of human epidermal growth factor receptor 2 
(HER-2) [1]. Since the tumor cells lack the necessary receptors, common treatments such 
as hormone therapy and drugs that target estrogen, progesterone, and HER-2 are 
ineffective  and chemotherapy is the main treatment option [2]. 
TNBC exhibits similar characteristics to basal-like BC with distinct pathological and 
clinical features that make this BC subtype an aggressive phenotype: the 5-year survival 
rate for TNBC is 70% lower than other BC subtypes which have 80% survival rates [2] 
Owing to its lack of expression of hormonal receptors and intrinsic properties, TNBC 
shows high metastatic capability and poor prognosis [3-6]. A large body of 
epidemiological evidence suggests that regular exercise protects against BC development 
[7-17]. 
Among the cancer preventive effects of physical activity (PA) are the reduction of 
adiposity, changes in endogenous hormones, in particular, the reduction of basal 
concentrations of circulatory sex hormones, metabolic hormones as well as inflammatory 
factors, all of which are known to be risk factors for BC [18]. 
In last few years it has been shown that contracting skeletal muscle releases myokines 
that exert their role in an autocrine, paracrine and endocrine manner [19]. In addition to 
their acknowledged role as mediators in the cross talk between muscle and fat, it has been 
suggested that myokines may also play a role in cancer protection [20, 21, 22]. 
In this regard, observational data show that physically active breast cancer survivors 
(BCS) have a 30–50 % reduced risk of disease recurrence and mortality [23, 24]. Hence, 
PA would seem to have a significant controlling effect on BC progression. 
PA might reduce systemic inflammation alone or in combination with a reduction in body 
weight or leading to a reduction in inflammatory cytokines in adipose tissue. Although 
PA may improve BC outcomes, no studies have provided mechanistic data to 
differentiate between different types of exercise and relative systemic responses, and very 
little is known about pathways and mechanisms linking PA and TNBC. 
The purpose of this study was to examine if systemic responses to acute endurance 
exercise before and after training in sedentary healthy women could modulate TNBC cell 
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proliferation, in vitro. Specifically, we stimulated BC MDA-MB 231 cell lines with 
serum obtained in healthy sedentary women pre- and post- High Intensity Endurance 
Cycling (HIEC) Test. 
 
 
2. Materials and Methods 
 
The subjects in the study were healthy sedentary women from the University of Urbino. 
The study was performed at the Department of Biomolecular Sciences (DISB) of the 
University of Urbino between September and December 2017 according to the guidelines 
of the Helsinki Declaration for research with human volunteers (1975) and after the 
approval by the Ethics Committee of the University of Urbino Carlo Bo (date of approval 
July 10, 2017). Following a medical health-screening, all participants provided written 
informed consent to participate in the study. 
 
Participants 
Twelve healthy sedentary women (age: 21 ± 0.8 years, body height: 160 ± 4.7 m, body 
mass: 53 ± 5.2 kg, BMI: 21 ± 1.2 kg/m
2
) were recruited for this study. 
The exclusion criteria included major cardiovascular disease risks, musculoskeletal 
injuries, upper respiratory infection, smoking or having taken any medication in the 
previous 3 months. 
None of the participants had performed any physical activity for at least six months prior 
to the start of the study. The participants were advised to maintain their dietary routine 
and were also instructed to refrain from all training activities except those sessions 
included in the experimental design. 
 
Outcome measures 
The outcome measures evaluated in this study were the effects on cell proliferation and 
viability of MDA-MB-231 BC cell lines. Cells were cultured with the sera of women 
obtained pre-exercise, immediately after exercise sessions and 4 h and 24 h post-exercise 
together with a physiological concentration of glucose. Cell proliferation was evaluated 
by cell count using a hemocytometer and trypan blue exclusion assay. 
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Preliminary testing 
The subjects were informed of the research activities and were asked to sign an informed 
consent form to undergo a preliminary medical examination to ascertain their suitability 
for participation in the study. During the first week in the laboratory the subjects 
underwent an anthropometric examination which included the measurement of body 
height (cm), body mass (kg), BMI (kg/m
2
), waist circumference (cm) of the major 
muscular groups (waist, thighs, legs, arms) and Bio-Electrical Impedance Analysis (BIA). 
In the second week the subjects performed a maximal incremental test to exhaustion on 
an SRM cycle ergometer (SRM Italia, Lucca, Italy), during which maximum oxygen 
consumption was measured by the Cosmed K4b2 metabolimeter (Cosmed Italia Srl). 
 
Experimental Design 
Incremental Test for VO2max, Pmax, and Lactate Thresholds 
Each subject performed an incremental test to assess maximal oxygen consumption 
(VO2max), lactate thresholds (to define the individual training intensity zones) and 
maximal power (Pmax), to determine the individual workloads for the experimental trial. 
The test was performed on an SRM ergometer (SRM Italia, Lucca, Italy). Subjects began 
cycling at 50 W, and power output was thereafter increased by 20 W every 3 min until 
volitional exhaustion or a drop in the cadence below 60 rpm. Oxygen consumption was 
monitored for the duration of the trial (breath-by-breath) using the Cosmed K4b2 
metabolimeter (COSMED, Rome, Italy), heart rate (HR) was recorded with the Polar RS-
800 heart rate monitor (POLAR, Kempele, Finland), and blood lactate was measured 
(before starting the test and within 30 s before the end of each stage) using the Lactate 
Pro portable blood lactate meter (Arkray, Kyoto, Japan) in micro blood samples drawn 
from the tip of the index finger according to the manufacturer’s instructions. VO2max was 
identified as the maximum value derived from the 15-breath moving average of oxygen 
consumption of the entire test, as suggested by Robergs et al. [25]. Blood lactate 
measurements were used to identify the training intensity zones, based on the following 
concentration values: zone 1, ≤ 2.0 mM, zone 2, >2.0 and < 4.0mM, zone 3, ≥ 4.0mM. 
HR was monitored to determine values corresponding to LT1 and LT2, as well as 
maximal heart rate (HRmax) [26]. Percentages of the Pmax were used to determine the 
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workloads to be undertaken during the experimental trials (e.g., power output (W) at a 
given % Pmax). 
The incremental test was repeated three days after the end of the training period to assess 
the training effects on VO2max, lactate thresholds and Pmax (useful to determine the new 
workloads for the experimental trial). 
 
High Intensity Endurance Cycling (HIEC) Test 
On the day of the experiment subjects arrived at the laboratory at 06.00 AM in a fasted 
state 2 h before the test. All the subjects then had a standardized breakfast (200 ml of 
fruit-juice and two slices of tart with marmalade (96g) (480 kCal, 88g CHO, 5g protein; 
10g fat), and a blood sample was collected just before starting the trial. 
HIEC tests were performed on a “Technogym Group Cycle™ Connect” equipped with a 
power meter (Technogym S.p.A., Cesena, Italy). Subjects completed an initial 2 min 
warm-up period allowing them to build up to the starting workload, followed by four 5 
min continuous progressive increments of cycling completed at a workload 
corresponding to 50%, 55%, 60% and 70% Pmax. This was followed by ten 90 s sprints 
(SPR) at a workload corresponding to 90% Pmax, separated by 180 s recovery (REC) at a 
workload corresponding to 55% Pmax. If a subject completed all 10 sprints, after a 3 min 
interval at 55% Pmax, a time to exhaustion step was undertaken at 90% Pmax. 
Exhaustion during the 10 sprints at 90% Pmax or the time to exhaustion at 90 % Pmax 
was defined as an inability to maintain power output within 5 W of the expected power 
and an inability to restore this power output within 15 s despite verbal encouragement. 
No feedback on elapsed time was provided, as this would have introduced potential bias 
with subjects targeting previous times. The power output during the experimental trials 
was controlled by the power meter display, with the subjects using a predefined cadence 
[27]. Blood samples were collected immediately after, and 2 h, 4 h and 24 h post-HIEC 
test (Figure 1). The HIEC Test was repeated three days after the final incremental test. 
 
Training Protocol 
36 indoor cycling training sessions were performed over a 9-week period. Training 
sessions were structured as follows (Figure 1): 
(A) 3 weeks of 3 sessions/week of 53.1 ± 1.3 min, 
(B) 3 weeks of 4 sessions/week of 59.1 ± 1.2 min, 
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(C) 3 weeks of 5 sessions/week of 68.2 ± 1.4 min. 
 
The 12 subjects were trained by an expert instructor whose aim was to have the subjects 
follow the same training program. The class was choreographed based on conventional 
principles (i.e., warm-up, systematic interval exercise, and cool-down) widely used in the 
indoor cycling community [28]. The training program for each session was designed 
following the same intensity distribution based on a polarized model, with 69 ± 3% of the 
session time spent in zone 1 (< LT1), 11 ± 2% spent in zone 2 (> LT1; < LT2), 20 ± 2% 
spent in zone 3 (> LT2) as described by Seiler et al. [26]. 
During the training sessions the HR of each subject (instructor included) was monitored 
using a Polar Team Pack 2 (POLAR, Kempele, Finland) and projected onto the wall. The 
subjects were asked to maintain the same HR intensity zone as the instructor. 
 
Figure 1. Experimental Design. 
 
 
Diet monitoring 
For the duration of the study subjects were asked to keep a daily food diary and their 
nutrient intake was monitored using the appropriate software (Metadieta). In general, 
subjects were not asked to change their eating habits, except in cases where an excessive 
or reduced protein intake was found, in which case the subject was asked to make 
changes. On trial days, breakfast was provided two hours before the acute session. 
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Blood profile 
Blood samples were collected pre-, immediately after and  4 h and 24 h post-exercise. 
The sera obtained were used to supplement culture medium for TNBC MDA-MB-231 
cells to evaluate cell proliferation. 
 
Cell culture experiments  
The MDA-MB-231 human breast adenocarcinoma cell lines (ER-, PR-, HER2-) were 
cultured in DMEM supplemented with 10% fetal bovine serum (FBS), 2 mmol/L L-
glutamine, 1 × MEM non-essential amino acid solution, 0.1 mg/ml streptomycin and 0.1 
U/L penicillin (growth media) and 1 mM sodium pyruvate. Cells were maintained in a 
humidified incubator (5% CO2) at 37 °C during a maximum of fifteen cellular passages . 
For the experiments, the MDA-MB-231 cells were seeded at 20.000 cells/well in 24-well 
plates. After overnight incubation, the culture medium was replaced with DMEM red-
phenol free with a physiological concentration of glucose (0.8 mg/mL) and with 5% of 
conditioned human sera collected pre/post-HIEC Test. After 48 hours, cells were counted 
by trypan blue exclusion assay using a hemocytometer. All cell culture materials were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Blood samples were collected in BD Vacutainer
®
 Plus plastic serum tubes, inverted 6 
times and allowed to clot for 30 min at room temperature. Serum was obtained by a 
centrifugation step at 1,000 x g for 15 min at 4° C and was then aliquoted and stored at -
80° C until the experiments. 
 
 
Statistical analyses 
 
One-way ANOVA followed by Dunnett's Multiple Comparison Test (p<0.001) were used 
to compare pre- and post-exercise cell proliferation at different times. Twelve subjects 
were recruited in the acute exercise study, and all the subjects with available blood 
samples (n=12 healthy women) were used in the training study. 
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3. Results and Discussion 
 
In this study we used the serum obtained from healthy sedentary women before and after 
a single session of HIEC (exercise session lasting about 75/80 minutes with alternated 
stages of high, 90% Pmax, and low intensity, 55% Pmax, ending with a time to 
exhaustion, 90% Pmax), to treat TNBC cells. 
The HIEC session was performed before and after 9 weeks of training, and the serum was 
added to a culture medium of MDA-MB 231 cells. This ex vivo approach allowed us to 
analyze the effect of systemic changes induced by exercise on the cellular viability of this 
type of aggressive tumour. 
The serum taken after the single HIEC exercise session significantly reduced the 
proliferation of MDA-MB 231 cells. This effect was particularly evident after the acute 
exercise, while the serum taken after 9 weeks of training, at basal level (before the single 
exercise session) showed only a slight insignificant reduction in cell proliferation (Figure 
3) compared to the serum taken at the pre-training basal level, when subjects were still in 
a sedentary state. Thus, cell proliferation of MDA-MB 231 cell lines after the single 
exercise session was significantly reduced and the experiments were reproducible (Figure 
2). In particular, the reduction in cell proliferation was observable immediately after 
exercise: the rate of cell proliferation decreased significantly by about 10-15% in the cells 
grown with the sera collected immediately after exercise. Moreover, 4 h after exercise, 
the proliferation rate decreased by about 24-25% compared to the cells grown with pre-
exercise sera, in both experimental conditions, i.e., pre- and post- training (unidirectional 
ANOVA followed by the multiple comparison test of Dunnett, p <0.001). The reduction 
in proliferation observed using the sera obtained 4 h after exercise was also maintained 
by the sera taken 24 h after exercise.  
The results of our study show that a single exercise session has a significant braking 
effect on the proliferation of cancer cells, in agreement with Dethlefsen C. et al., 2016 
[29]. The acute exercise protocol examined in a part of the 2016 study by Dethlefsen C. 
et al. consisted of a concurrent protocol lasting 2 h: 30 min of warm-up, 60 min of 
resistance exercises (3 sets of 8-10 repetitions at 70-90% of 1-RM) followed by 30 min of 
high intensity pedaling on a cycle ergometer.  
An ex vivo study described by Rundqvist H. et al., 2013 [30] showed that the incubation 
of prostate cancer cells (LNCaP) with serum obtained after 65 min of aerobic exercise on 
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the cycle ergometer, performed by young and healthy subjects with increasing intensity 
(20 min to 50% VO2max and the following 40 min to 65% Vo2max), resulted in a 31% 
inhibition of prostate cancer cell growth (p <0.05) compared to incubation with a pre-
exercise serum pool. 
The exercise protocol described by Rundqvist H. et al., 2013 was recently applied in a 
preliminary study in sedentary premenopausal women; the exercise serum (taken 
immediately after and 2 h post-exercise) led to a reduction in cell proliferation. In 
particular, the serum taken 2 h after exercise inhibited the proliferation of MDA-MB 231 
cell lines by about 10% compared to the pre-exercise serum (31). 
 
 
  
 
Figure 2. MDA-MB-231 cell proliferation analysis. Sera were collected before, immediately 
after, and 4 h and 24 h after (post) the HIEC Test (Pre- and Post-training). Cells were stimulated 
with 5% of conditioned human sera collected pre/post-HIEC Test before (pre) and after (post) 9 
weeks of indoor cycling training. Data are expressed as cell count relative to cells stimulated with 
pre-HIEC Test serum (set as one-fold). Statistical significance was tested by one-way ANOVA 
followed by Dunnett's Multiple Comparison Test;  *** p<0.001. 
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Figure 3. Basal effect of human sera on MDA-MB-231 cell proliferation. Cells were stimulated 
with 5%  conditioned human sera collected at rest before (pre) and after (post) 9 weeks of indoor 
cycling training. Data are expressed as total cell count. Statistical significance was tested by two-
tailed paired t-test (p<0.05). 
 
 
Furthermore, data from our study show that the HIEC exercise session resulted in a 
release of creatine kinase (CK) in the blood immediately after exercise (Figure 4). 
Our results related to the CK muscle damage marker show a significant increase between 
pre- and post-exercise (13.33 ± 5.8 vs 24.91 ± 8.6; p = 0.003) in the samples taken during 
the acute session before the training period; the CK values return to baseline values after 
4 h  and increase again after 24 h, i.e., 24 h after the HIEC Test (13.9 ± 6.3 vs. 21.4 ± 9.7 
p = 0.00) (Figure 4). In the samples taken during the acute exercise session carried out 
after the training period, we also found a significant increase in CK between pre- and 
post-exercise (22.2 ± 7.5 vs 32.2 ± 7.0 p = 0.00) and then a return to baseline values after 
4 h and a further reduction after 24 h (20.8 ± 5.0 vs 13.8 ± 5.4 p = 0.01) (Figure 4). 
The presence of CK in the blood is generally used as an indirect marker of muscle 
damage. In fact, individuals who regularly participate in intense exercise at high volume 
tend to have significantly increased CK base levels compared to sedentary or moderately 
active individuals [32]. Elevated serum CK levels were also found after regular exercise 
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in pre-menopausal women compared to sedentary individuals of the same age [33]. This 
suggests that the release of CK into serum is a normal reaction to regular exercise; 
however, the molecular mechanisms that trigger its release after high intensity exercise 
are not yet clear and further investigation of these mechanisms could provide important 
insights into TNBC. Interestingly, in a large study by Pan H. et al., 2013 [34], an 
association between serum CK levels and BC was observed. The authors found that 
serum CK levels in BC patients were significantly lower than those with benign breast 
disease. Therefore, it is possible to deduce that CK levels represent an important part of 
the immune response that influences the development and progression of BC and low CK 
levels would seem to favor pathways to tumorigenesis [35]. Hence, an increase in serum 
CK levels due to mechanisms induced by muscle contraction may exert protective action 
against TNBC. 
 
 
 
 
 
 
Figure 4. CK dosage. Sera were collected before, immediately after, 4 h and 24 h after the HIEC 
Test (Pre- and Post-training). 
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4. Conclusions 
 
This study provides strong evidence of the protective effects of exercise against a 
particularly aggressive tumor, TNBC, which is considered less sensitive to therapies. 
There are few investigations that have dealt with this area of research rigorously, 
particularly in TNBC cell lines. Our investigation showed that systemic changes, 
occurring during and performance of a 75/80 min HIEC Test, had inhibitory effects on 
BC viability in the tested TNBC cell lines, and this effect  was maintained for at least for 
24 h. Hence, we propose that  high-intensity exercise of 75/80 min could have a positive 
effect on TNBC outcomes. 
This study provides new data on  factors released through exercise, which may have 
inhibitory effects on cancer cell proliferation. Such factors could have therapeutic value 
for TNBC survivors. In the future, research should focus on a detailed characterization of 
different types of exercise, aiming to identify potential exercise-induced anti-oncogenic 
factors and establishing how these are regulated by different modes of exercise. 
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Abstract 
 
Background: Healthy lifestyle habits have been associated with improved quality of life 
for breast cancer survivors (BCS). Physical activity (PA) during and following Breast 
Cancer (BC) treatments has been shown to improve both physical and emotional health, 
and overall quality of life. It can help to improve body weight and muscle strength and 
attenuate physical side effects of BC treatments, such as fatigue, pain and lowered bone 
density. The aim of this pilot study was to evaluate the effect of a structured PA 
intervention on measures of physical performance and quality of life among BCS 
attending the Breast Unit, University Hospital of Ancona. 
Material and methods: Twenty sedentary women with BC (age range: 56.05 ± 11.56 
years) who had undergone primary surgery were recruited consecutively at the Breast 
Cancer Unit facilities of the University Hospital of Ancona, between February and March 
2018 for a controlled pilot study. Patients, that were not engaged in physical training for 
six months previously, belonged to either a control (n=10) or an intervention arm (n=10). 
Patients in both arms were assigned to sixteen weeks of “Lifestyle Program”, consisting 
of lifestyle counseling, periodical functional tests and follow-up. The intervention arm 
(IA) underwent eight weeks of supervised exercise program and eight weeks of follow-
up. The supervised exercise program includes two sessions/week (~60 min) of aerobic, 
resistance and flexibility exercise in the same session (circuit training program) and one 
session per week devoted to aerobic unsupervised training. The control arm (CA) 
received only lifestyle counseling and the periodical tests. Participants were evaluated at 
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the beginning of the study to establish a baseline and reevaluated after four, eight and 
sixteen weeks. 
PA level (evaluated by the International Physical Activity Questionnaire, IPAQ), quality 
of life (tested by QoL - 36-Item Short Form Health Survey questionnaire, SF-36), and 
functional exercise capacities (tested by 6-minute Walk Test, 6MWT; Hand Grip test; Sit 
and Reach test) were assessed along sixteen weeks for both arms: at baseline, after four, 
eight and sixteen weeks. 
Results: At baseline, the two groups showed comparable outcome measures results. After 
the first four-week of follow-up, the quality of life measured through SF-36 improved in 
both groups, but the “General Health” domain (D8) significantly more in the IA rather in 
the CA (F 8.0; p=.01) and the amount of daily physical activity quantified in MET 
increased significantly in both groups (IA: Z = -53.0; p <.0001; CA: Z = -2.2; p = .03); 
however, in the IA subjects the MET value increased two-fold compared to the CA 
subjects (F = 21.0; p = .0002). 6MWT highlighted that subjects of the IA improved 
significantly more than CA (F=7.6; p=.01) increasing on average by 49 meters [range: 
190: -4] while the CA subjects worsened on average by about 15 meters [range: 42: -95] 
compared to baseline. Also, right hand squeeze force improved significantly in the IA (Z 
= -2.66; p = .008), while no differences were found within and between groups in the Sit 
and Reach test. All subjects reported that they appreciated the training or counseling. 
Conclusions: The “Lifestyle Program”, including exercise counseling and supervised 
exercise program, improved functional exercise capacity and motivated BCS to adopt a 
healthier lifestyle based on regular PA. 
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1. Background 
 
Breast cancer (BC) is the most common cancer among women worldwide [1]. Breast 
cancer survivors (BCS) therefore face unique challenges to their health and well-being. A 
large body of evidence shows that physical activity (PA) is able to improve the psycho-
physical well-being of BCS [2-9]. The beneficial effects induced by exercise are 
commonly attributed to long-term adaptations (i.e., months/years) and related to 
improvements in cardiorespiratory fitness, strength, body composition and resistance to 
fatigue [10-12]. In addition to these training related improvements, exercise also yields 
short-term effects (i.e., hours/days) mainly due to muscles releasing molecular factors 
induced by contraction. Indeed, during exercise transient but marked increases in a wide 
range of circulating hormones, cytokines, and immune cells occur [13]. 
It has been reported that these systemic responses are able to reduce BC viability [14]. 
Although the role of PA in improving BC outcomes is well documented, it is not yet 
known which anti-oncogenic mechanisms are triggered by acute exercise or long term 
training. 
In general, reviews and meta-analyses tend to group PA and exercise interventions into 
general categories, and infrequently examine the specific exercise protocols employed in 
the studies. The American Cancer Society (ACS) recommends that cancer survivors 
engage in a minimum of 150 weekly minutes of moderate-intensity exercise [15, 16]. 
However, PA levels are generally low among BCS, and many women decrease their PA 
following diagnosis [17, 18]. 
Thus, it is of primary importance to identify an appropriate promotion and prescription of 
regular PA for BCS to improve their prognoses, response to therapy, and quality of life 
(QoL). 
For this purpose hospitals need to have an integrated team of professionals, including a 
physiologist and a qualified and specialized trainers of exercise and sport science, who 
can approach the disease not only from a pharmacological and surgical point of view. It is 
important that PA becomes an increasingly personalized tool, like drugs use, and it 
should be included in a personalized lifestyle program. To achieve this goal, PA 
counseling, which could promote both physical and mental well-being, must be integrated 
into primary care. Moreover, PA counseling is important for most patients and its benefits 
can translate into considerable benefits for the health of the community in terms of both 
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improved individual health and reduction in the economic and social costs of physical 
inactivity. 
The “Lifestyle program” aims to promote positive lifestyle and behavior changes that are 
the basis of an individual’s motivational readiness and will to integrate PA into daily 
routines. 
The primary aim of this pilot study was to evaluate the effects of a structured PA 
intervention, in particular, a circuit training program, on measures of physical 
performance and quality of life among BCS attending the Breast Unit, University 
Hospital of Ancona. 
The secondary aim was the introduction of targeted PA counseling for BCS in order to 
optimize recruitment and adherence to a healthy lifestyle, as well as to improve health 
outcomes in BCS. Furthermore, the present study proposed a PA diary as a reliable and 
simple tool to assess the level of daily PA and the effect of PA counseling. 
 
 
2. The Study Design 
 
This pilot study was a controlled trial with two arms, the control arm (CA) and 
intervention arm (IA). After the oncological or physiatrist visit, BCS were assigned to 
sixteen weeks of “Lifestyle Program”, consisting of lifestyle counseling for both groups 
and supervised exercise programs for the IA participants. Those patients who did not give 
the consensus to participate in the supervised exercise programs organized at the Ancona 
University Hospital were enrolled in the CA, those who ensured adhesion to the proposed 
training sessions were enrolled in the IA. All reasons of denied consensus were recorded 
by the assessor clinicians. 
PA level (International Physical Activity Questionnaire Short Form, IPAQ-SF) and 
functional exercise capacities (6-Minute Walk Test, 6MWT; Hand Grip test; Sit and 
Reach test) were assessed along sixteen weeks for both arms: at baseline, after four, eight 
and sixteen weeks. Supervised exercise was administrated to the IA for the first eight 
weeks of the “Lifestyle program” after one week of familiarization sessions. The PA 
intervention was planned individually in terms of the Frequency (F), Intensity (I), Time 
(T), Type (T), Volume (V), and Progression (P), known as the FITT-VP principle of the 
American College of Sports Medicine [19] and included a circuit training program. The 
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intensity of aerobic exercise on a treadmill was prescribed as % of the average speed of 
the 6MWT [20]. Resistance and flexibility exercises were included in the circuit training 
program as well. 
 
2.1. Methods 
 
2.1.1 Participants and Setting 
Twenty sedentary women with BC (age 56.05 ± 11.56 years; body mass 67.9 ± 13.23 kg; 
body height 163.1 ± 6.04 m; waist circumference 93.55 ± 10.26 cm; BMI 25.49 ± 4.46 
kg/m
2
) (Table 1) were recruited from the Department of Medical Oncology, University 
Hospital of Ancona between February and March 2018 and randomized to CA (n=10 
women) or IA (n=10 women) for a controlled pilot study. Inclusion criteria included: 
histologically conﬁrmed diagnosis of BC; woman between 30 and 70 yrs of age; 
mastectomy and/or quadrantectomy +/- lymphadenectomy surgery; both with positive or 
negative lymph nodes; ≤5 year post-surgery status; time since completion of 
chemotherapy ≥6 months; sedentary ≥6 months. 
Major exclusion criteria were contraindications to exercise training; bone and brain 
metastases, or symptomatic cardiac disease. 
The Institute’s Ethics Committee approved the study. All participants were informed 
about the objectives of the study and provided written consent was obtained.  
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Table 1. Clinical characteristics of the pilot study population 
Sample characteristics (n=20)   
Age (years) 56.05 ± 11.56   
Body mass (kg) 67.9 ± 13.23   
Body height (m) 163.1 ± 6.04   
Waist circumference (cm) 93.55 ± 10.26   
BMI (kg/m
2
) 25.49 ± 4.46   
Note: Data are reported as means ± SD. BMI: body mass index. 
 
 
Measures 
The assessment included: (1) health and lifestyle questionnaires, (2) test of functional 
exercise capacity and PA levels, (3) training in the use of treadmill. The measures are 
briefly summarized hereafter. 
 
 
Health and lifestyle questionnaires 
Participants completed three questionnaires: (1) (Baseline) Health Questionnaire which 
included demographic characteristics, menopausal status, menstrual and reproductive 
history, personal health history, family history of cancer, nutrition information, and 
smoking and alcohol use histories; (2) IPAQ, used for monitoring health-related PA and 
sedentary behavior [21, 22]; (3) SF-36, used to measure quality of life (QoL) and general 
health [23]. 
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Health-related fitness assessments 
The functional exercise capacities and PA levels were measured objectively using 
standardized testing protocols. The assessments were typically completed in the 
following order: resting blood pressure and heart rate (HR); anthropometric data (age, in 
years; body mass, in kilograms; body height, in meters; waist circumference, in 
centimeters; BMI, in kg/m
2
); flexibility (Sit and Reach Test); grip strength (Hand Grip 
Test); cardiovascular fitness (6MWT). 
 
Muscle fitness and flexibility 
Flexibility and muscle strength evaluations were performed with easily executable and 
reproducible tests, namely the Sit and Reach for flexibility [24] and the Hand Grip test 
[25], which uses a hand dynamometer to estimate the overall static strength of the upper 
limbs (Jamar® Hydraulic Dynamometer). Handgrip strength test (HGS) is easy to 
perform, non-invasive, low cost and it is also used as screening tool to track patients’ 
deterioration of health [26] and as predictor of post-operative morbidity [27]. 
 
Cardiovascular fitness 
The 6MWT is a practical and simple test that measures the distance a patient can walk 
rapidly on a hard flat surface in a period of 6 min. Currently, guidelines for the 6MWT 
established by the American Thoracic Society (ATS) recommend the use of an indoor or 
outdoor corridor with a flat surface 30 m in length [28]. Patients were instructed to walk 
along the corridor at their own pace, trying to cover as much distance as possible in 6 
min. This test reflects the subject’s functional exercise level for daily physical activities 
[29] because most everyday activities are performed at sub-maximal levels of exertion. 
The following parameters were recorded during the 6MWT: distance covered (6MWD), 
peak heart rate (HRpeak), which was measured using a heart rate monitor, systolic and 
diastolic blood pressure at rest and at the end of the test, and self-perception of effort 
(Borg Scale) [30]. 
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Assessment timing 
The assessment was provided at the baseline, at the start of the “Lifestyle Program”; after 
the first four weeks of follow-up (4-weeks) at the end of the PA program, i.e. after eight 
weeks of follow-up (8-weeks) and at the end of the “Lifestyle Program” (16-weeks), i.e. 
at the sixteenth week follow-up.  
 
Familiarization sessions 
The subjects enrolled in IA familiarized themselves with treadmill walking three times a 
week for one week. Walking duration was increased during the familiarization period as 
tolerated, up to a maximum of 30 min, with a maximum of three rest periods. In the first 
session, walked at a self-selected pace on a treadmill, and in the subsequent two sessions, 
individuals were encouraged to train at an intensity of 50-60% of the average speed of the 
6MWT. 
In the same sessions, participants familiarized themselves with resistance and stretching 
exercises, and each patient was instructed on how to correctly perform both types of 
exercise. 
 
2.1.2 Intervention 
 
The “Lifestyle Program” coordinated by the Oncologists and Physiatrists of the Breast 
Cancer Unit, University Hospital of Ancona, was implemented with exercise counseling 
and a supervised exercise program to improve functional exercise capacity [31]. A diary 
of PA was also proposed to monitor the patient’s PA level and help BCS to exercise 
regularly. 
 
Physical Activity Diary 
The Diary contains information about the benefits of exercise, the amount of exercise that 
is recommended for patients, types of exercises and practical tips to encourage BCS to 
exercise regularly. The booklet cover (Figure 1a) contains the diary name, “Active 
Women”. The cover image was selected by research team and represents a group of BCS. 
The first page of the Diary (Figure 1b) provides a summary of recommendations for BCS, 
while the second page (Figure 1c) contains instructions on PA programming and 
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describes the “Talk test”. These sections aim to increase awareness of the many benefits 
of exercise for BCS. In the light of the scientific evidence on the benefits of PA, the PA 
diary is presented and women are invited to complete the diary for four consecutive 
weeks (Figure 1d). The following session includes instructions (Figure 1e) for completing 
“My Physical Activity Diary”. Finally, instructor, before delivering the PA diary, 
completes the table with the clinical characteristics of the woman (body height, body 
mass, waist circumference, BMI) and invites the woman to complete “My Physical 
Activity Diary”, indicating 'Starting time', 'Type of PA', 'Duration' and 'Comments or 
notes' for four consecutive weeks (Figure 1f). 
 
 
Figure 1. Physical Activity Diary: (a) cover; (b) recommendations; (c) instructions on PA 
programming; (d) (e) and (f) instructions for completing the diary “My Physical Activity Diary”. 
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Physical Activity Interventions 
Cancer survivors were enrolled in a CA and an IA. For both groups an exercise 
counseling activity was offered consisting of an individual meeting (30 min), based on 
principles of narrative and cognitive theory [32]. The counseling was held by a qualified 
and specialized exercise trainer, who provided the patient with the appropriate 
information and support for practicing regular PA. At the end of the counseling session, 
the PA diary was given to each patient. 
Subjects in the IA then started on a program of PA and exercise, training three times a 
week on Monday, Wednesday (supervised sessions) and Friday (unsupervised session, 
monitored by PA diary) for eight weeks. The training protocol was developed based on 
the recommendations of the ACSM [19] and its general aim was to have subjects trained 
regularly for at least 3 days a week (in accordance with the main guidelines - at least 150 
min/week of moderate intensity exercise or 75 min/week of vigorous intensity exercise). 
Subjects in the CA maintained their routine and were not involved in any supervised 
training. 
The supervised training sessions were held at the gym of the Neurorehabilitation Clinic - 
University Hospital of Ancona and were structured as follows: each session lasting about 
60 min and exercise intervention consisted in circuit training that included both aerobic 
and resistance exercises. Each training session was held in groups and on non-
consecutive days, for eight weeks. The women of IA completed a total of sixteen 
supervised training sessions. 
 
Procedures 
The supervised exercise sessions were structured as follows: a 5 min warm-up phase 
during which women performed dynamic warm-up exercises for the joints and for the 
main muscle groups (both upper and lower body) (Table 2); the main part consisted of 45 
min of circuit training (Table 4); a final 5 min cool-down phase where women performed 
static stretching exercises mainly for the pectoral muscle, hamstrings and lumbar region 
(Table 3). All the exercises were explained and previously demonstrated by a qualified 
specialized exercise trainer and the women were invited to practice the exercises for a 
few minutes before starting the first training session. 
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Table 2. Dynamic warm-up exercise 
1. Side-to-side neck tilt. Tilt neck towards one shoulder and then towards the other. 
2. Neck turn. Turn head to one side, keeping chin at the same level. 
3. Shoulder rolls. From a position of proper alignment, roll shoulders upwards, then 
back, then downwards in a fluid motion. 
4. Raise body on toes and swing alternating arms. 
5. March on the spot. Keep knees up and move the opposite arm with the opposite knee. 
 
Table 3. Static stretching exercises 
1. Head chest stretch. Seated or standing, interlock your fingers, bend your elbows 
and raise your arms above your head. Gently squeeze your shoulder blades 
together and move your elbows and hands backward. Vary the height of your 
hands to involve shoulders and/or chest (hands behind head, hands on top of head, 
hands a few inches above head). 
2. The simple hamstring stretch: sit on the floor with both legs out straight. Extend 
your arms and reach forward by bending at the waist as far as possible while 
keeping your knees straight. Relax back into the starting position and repeat. 
3. Cat-camel back stretch. On hands and knees, slowly alternate between arching 
and rounding your back so that all three sections of your spine-lumbar (lower), 
thoracic (middle) and cervical (upper)-extend together and then flex together. 
4. Supine cross-leg spinal twist. Lying on your back with knees bent and feet on the 
floor, stretch arms out to sides, palms facing down. Cross right knee over left 
knee. Shift hips to the right and drop knees to the left. 
5. Twisting glute stretch. Sitting on the floor, with your legs stretched out in front of 
you, bend one knee, keeping the other extended. Drape the opposite arm across 
the bent knee and twist toward it until you feel your glute muscles stretching. 
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Circuit training protocol 
The circuit training protocol included eight stations (seven stations dedicated to resistance 
exercise and one station for aerobic exercise), repeated twice in each training session 
(Table 4). The exercise routine was designed to involve the whole body and to alternate 
opposing muscle groups work and rest periods. The goal was to make the lower body 
work while the upper body was not called into play, and vice versa. In order to obtain 
aerobic and metabolic benefits, each station consisted of very few breaks between the 
exercises and the women were given three levels of difficulty at each resistance station 
(Table 4) so that the intensity of the exercise was approximately customized for each 
patient. 
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Table 4. Circuit training session  
Phase/Exercises Exercise Time Series Intensive progression (level 1/2/3)* Materials 
Warm-up  5 min    
Main part  45 min    
Circuit training stations 
a. Push-ups  30s; 10-20s Rest 2 Wall push-ups/ Push-ups from 
knees/Push-ups 
Met 
b. Squats  30s; 10-20s Rest 2 Wall-squats/Bodyweight 
squats/Counterbalance squats 
 
Medicine 
ball (MB) - 
2kg 
c. Triceps extension  30s; 10-20s Rest 2 Low/ medium/ high resistance 
 
Elastic band 
(Therabands) 
d. Crunches  30s; 10-20s Rest 2 Arms stretched forward/ chest/ 
backwar 
 
Mat 
e. Bridging  30s; 10-20s Rest 2 Basic bridge (Two legs)/Single 
Leg bridge/ Basic bridge with band 
 
Mat and 
Elastic band 
(Therabands) 
f. Calf-Raise 30s; 10-20s Rest 2 Wall Calf-raise, doubles legs/ Calf-
raise single leg/ Calf-raise single 
leg, knee straight 
 
Step 
g. Rowing  30s; 10-20s Rest 2 Low/ medium/ high resistance Elastic band 
(Therabands) 
Aerobic exercise     
Treadmill walking 15-20 min 2 80%–110% of the average 6MWT 
speed 
Treadmill 
Cool-down  5 min    
Static stretching          
* see text for details about intensity progression mode. 
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Each resistance exercise was performed for 30s and was followed by 10 to 20s of rest 
between one exercise and the other (gradually reduced during training). During the 30s of 
exercise, women were invited to complete the highest possible number of repetitions in a 
controlled manner up to the maximum allowed speed. All participants began the 
intervention program exercising at the first level of difficulty. When the participant was 
able to reach the maximum exercise speed for the given time she was instructed to adopt 
the next intensity level in the following exercise session. Aerobic exercise was performed 
on a treadmill (Runner EE-0720 MTR, Italy) and walking intensity was based on the 
average speed of the 6MWT [20]. The duration of the walk varied from a minimum 15 to 
maximum 20 min per session and the walk was repeated twice during the circuit protocol. 
The walking speed was increased by 10% during the eight weeks of training considering 
the average speed reached during the 6MWT at baseline and after four weeks of training. 
During the first four weeks of training, the walking speed was set considering the average 
speed during the 6MWT at baseline and was increased as follows: first week, 80% of the 
average speed of the 6MWT; second week, 90% of the average speed of the 6MWT; third 
week, 100% of the average speed of the 6MWT; fourth week, 110% of the average speed 
of the 6MWT. In the following four weeks, the intensity was increased as in the first 
four-weeks, but the walking speed was set considering the new average speed reached 
during 6MWT performed after the first four-week intervention. During aerobic exercise 
the Borg scale was shown (values from 6 to 20), to allow subjects to describe the 
intensity of their exertion and the operator to identify a given percentage of the maximum 
heart rate (HRmax) [30]. Moreover, during the aerobic exercise the “Talk test” was also 
proposed: this allowed the subject to focus on the frequency of their breathing and thus to 
become aware of its intensity (this test was also prescribed in the PA diary as a useful 
means to set the intensity of autonomous exercise) [33]. 
 
Statistical Analysis 
Statistical analysis was performed using StatView SAS software (version 5.0.1.). 
Descriptive analysis of clinical characteristics (mean, standard deviation) was performed 
and variables were found to be normal for age, body mass, body height, waist 
circumference, BMI. The analysis of the intra-group comparison was performed using the 
Wilcoxon signed-rank test, applied to non-parametric variables. The Friedman Test was 
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used to analyze the differences between the times in the intervention arm. Analysis of 
variance (ANOVA) for repeated measure was performed to obtain intergroup comparison 
(ANOVA for repeated measure, followed by Dunnett's Multiple Comparison Test; p 
<0.05). 
Specifically, the results are presented after 4 weeks for both groups. The control group is 
still being completed and we will publish our results of the complete study, once finished. 
 
 
3. Results 
 
Baseline Assessment Results 
At baseline no differences were find as for demographic and clinical data between the 
two groups. Subjects of the CA chose to not participate to the PA at the Hospital because 
of yet engaged in a autonomous PA (n=2) or because of logistic reasons, they live too far 
from the Hospital to reach it every weeks (n=8). 
36-Item Short Form Health Survey questionnaire (SF-36) 
The quality of life assessed by the SF-36 scale showed that at baseline the two groups 
were comparable in the different scales of the perception of well-being. After four weeks 
both groups had improved in terms of ‘Role limitation due to emotional problems’ (D3), 
Energy fatigue (D4), Emotional well-being (D5), while only the IA subjects improved in 
terms of ‘Physical functioning’ (D1), ‘Role limitation due to physical health’ (D2), 
‘Social functioning’ (D6), ‘Pain’ (D7) and ‘General health’ (D8). In the D8, a significant 
positive effect was found for the IA subjects with respect to CA (F 8.0; p=.01) (Figure 2, 
A). 
International Physical Activity Questionnaire (IPAQ) 
At baseline, the amount of daily physical activity quantified in MET was similar between 
the two groups. After four weeks, in both groups, the MET were significantly increased 
(IA: Z = -53.0; p <.0001; CA: Z = -2.2; p = .03); however, in the IA subjects the MET 
value increased two-fold compared to the CA subjects (F = 21.0; p = .0002) (Figure 2, B). 
After eight weeks of intervention the patients in the IA maintained the level of activity 
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which then tended to decrease two months after the end of the training; however, it 
remained higher than the baseline (Chi2 = 26.3; p <.0001). 
 
 
Figure 2. Health and lifestyle questionnaire results. SF-36 – D8 = ‘General health’, show a 
significant positive effect was found for the IA subjects after 4-weeks of intervention (A). IPAQ, 
International Physical Activity Questionnaire: the IA subjects the MET value increased two-fold 
compared to the CA subjects (F = 21.0; p = .0002) after 4-weeks of intervention (B). 
 
 
Physical Activity Diary 
The PA diary monitored daily PA from the first day after PA counseling. The results 
were translated into MET/week. The formal analysis of the data using comparative 
statistics did not show significant differences, but St. Err and Std. Dev were very high in 
the CA subjects. The amount of daily physical activity quantified in MET increased 
significantly in both groups (IA: Z = -53.0; p <.0001; CA: Z = -2.2; p = .03); however, in 
the IA subjects the MET value increased two-fold compared to the CA subjects (F = 21.0; 
p = .0002). The descriptive analysis of the data shows that three subjects the IA increased 
the MET from the first to the fourth week by about 1500 MET, while the others remained 
stable. In the CA subjects, after the first week there is great variability in behavior: three 
subjects did not perform any physical activity (MET ~ 0), two performed very intense 
activity (MET ~ 10000), while the others performed moderate activity (3000-4000 MET). 
At the fourth week the two patients who had carried out intense activity were no longer 
active (MET ~ 0), two increased from the baseline activity by about 1500 MET, six 
subjects did not change their activity level, including three patients who were completely 
sedentary (Figure 3). 
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Figure 3. Data obtained from “My Physical Activity Diary”. The PA diary monitored daily PA 
from the first day after PA counseling. The results were translated into MET/week for the 1a and 
the 4a-week in the IA and CA. The amount of daily physical activity quantified in MET increased 
significantly in both groups (IA: Z = -53.0; p <.0001; CA: Z = -2.2; p = .03); in the IA subjects 
the MET value increased two-fold compared to the CA subjects (F = 21.0; p = .0002). 
 
 
Six-Minute Walk Test (6MWT)  
Analysis of the results obtained for the 6MWT showed that five subjects in the IA 
improved over 30 meters, after four weeks of intervention (MCID according to Bohannon 
RW et al., 2017)[34] and no subject’s performance worsened compared to the baseline. 
Overall, subjects in the IA improved on average 49 meters [range: 190: -4], while 
subjects in the CA worsened on average by about 15 meters [range: 42: -95]. In the CA, 
only two subjects improved by more than 20 meters, while four subjects showed a 
significant drop in performance (less than 20 meters compared to baseline); the difference 
in walked meters between the two groups after four weeks of intervention was 
statistically significant (Z = -2.6; p = .009, Figure 4, A). In agreement with this data, 
subjects in the IA showed a positive improvement trend over time. This statistically 
significant result is evident after four weeks of intervention compared to baseline (Z = -
2.1; p = .02) (Figure 4, A) and is maintained through eight weeks of intervention (Chi2 = 
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12.0; p = .006). The intra-group comparison in the CA showed no statistically significant 
difference between the first four weeks and baseline evaluations (Figure 4, A). 
 
Sit-And-Reach Test (SRT)  
Results for the Sit and Reach Test showed no significant amelioration after four weeks in 
both groups, although a positive trend of improvement over time in the IA subjects is 
observable throughout the period of supervised intervention, although it notable a 
decreasing trend during the unsupervised period (Figure 4, B). 
 
Hand Grip Strength (HGS)  
The results of the Hand Grip Test (HGS) clearly showed that the right hand force 
improved significantly in subjects in the IA (Z = -2.66; p = .008) (Figure 4, C-D). 
Overall, the right hand of subjects in the IA showed a positive trend of improvement over 
time from baseline to eight weeks of intervention: Chi2 = 18.1; p = .0004 (Friedman test). 
The hand force however tends to decrease in both hands two months after the end of 
training. The left hand of IA subjects showed a positive trend from baseline to eight 
weeks of intervention: Chi2 = 10.1; p = .01, which tends to decrease in the two months 
following the training period. The CA subjects did not show statistically significant 
changes in force in either hand (Figure 4, C-D). In both groups, no statistically significant 
differences emerged between the force of the operated limb and the contralateral. 
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Figure 4. Functional exercise capacity tests results. 6MWT (6-minute Walk Test), show a 
statistically significant (Z = -2.6; p = .009) in the difference in walked meters between the two 
groups after 4-weeks of intervention (A). Sit and Reach Test (SRT) show no significant 
amelioration after 4-weeks in both groups (B). Hand Grip strength (HGS) (Kg) show a 
statistically significant in the right hand of subjects in the IA (Z = -2.66; p = .008) after 4-weeks 
of intervention (C); the left hand of IA subjects showed a positive trend from baseline to 4-weeks 
of intervention (D). In both groups, no statistically significant differences emerged between the 
force of the operated limb and the contralateral. 
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4. Discussion 
 
Lifestyle can play an important role in BC prevention, and one of the modifiable factors 
that can have a strong impact on the disease is PA. 
An increasing number of studies worldwide highlight the importance of PA in 
counteracting BC, and there is a large body of scientific evidence showing that PA plays 
a fundamental role in the promotion of health and wellbeing, prevention, treatment and 
the reduction of the risk of recurrence. 
Based on these emerging data, physicians and other health professionals have a moral, 
ethical and professional obligation to inform patients of the risk of being physically 
inactive and to provide them with the right exercise prescription. In fact, although the 
healthcare community often provides recommendations on PA for patients with chronic-
degenerative diseases, it has not yet developed a health prevention plan for cancer 
patients after surgery including a precise exercise and PA prescription. To date, PA is 
recommended based on general guidelines provided by the Health Ministry or the 
American College of Sports Medicine for a specific population and healthcare 
professionals assume that patients fully adhere to the exercise protocols provided to them. 
However, this does not happen in practice; a systematic review of the literature shows 
that self-reported measurement of adherence to exercise is not a valid and reliable 
measure to support patients undertaking a PA program that provides optimal doses of 
exercise [35]. Moreover, recording self-reported PA using a simple diary is not a valid 
lifestyle change tool. In fact, as our study shows, after patients have received PA 
counseling and a diary, they perceive the importance of an active lifestyle; nevertheless, 
they fail to maintain the right levels of PA recommended showing sudden increases 
and/or drastic reductions in PA. An inconsistent irregular exercise program, especially 
with spikes in MET and uncontrolled HR, could pose cardiovascular risks and potentially 
damage patient health rather than providing a powerful means of prevention as 
demonstrated in the literature. 
To be successful in the promotion of exercise it is essential that, alongside the patient’s 
clinical program and initial counseling session on PA, a structured educational program is 
needed. Our study demonstrates the importance and effectiveness of an exercise program 
provided in the hospital, prescribed and supervised by a qualified and specialized exercise 
trainer, who starts working with the patient at the end of her therapeutic regime and then 
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continues to provide support to help the patient move gradually towards an active 
lifestyle. Numerous studies have highlighted the importance of PA at different stages of 
the disease [4] and how different types of exercise can improve the prognosis and reduce 
the risk of both metastasis and recurrence. Patients with BC receive various forms of 
medical therapy, such as surgery, chemotherapy, hormone therapy, antibodies and/or 
radiotherapy, and have to deal with various side effects such as fatigue [36]. In addition, 
after diagnosis and treatment, patients begin to decrease their PA level, remaining 
physically inactive [37]. Movement enhances the subject’s sense of well-being acting on 
a mental level and in terms of controlling the progression of the disease. The promotion 
of exercise during the therapeutic treatment, with suitable spaces within the clinical 
facilities, where patients can move and train safely, should become an essential part of 
cancer care. 
 
 
Limitations of the study 
 
On the basis of the results obtained, we can state that the proposed exercise protocol was 
effective in achieving the pre-established objectives. However, although the training 
program led to improvements in the outcomes foreseen by the study, the exercise 
protocol was designed on the basis of sub-maximal and non-maximal tests, and thus had 
limitations related to the personalization of the exercise intensity adopted during the 
workout. Regarding improvements in muscle tone, we could only offer exercises with 
bodyweight or with small pieces of equipment. The intensity of the load, during counter-
resistance exercises, was gradually increased by using small overloads or resistances (a 
medicine ball or elastic bands). Undoubtedly, carrying out a maximum oxygen 
consumption test would have ensured better personalization of the aerobic intensity 
prescribe for treadmill exercise. Furthermore, the use of isotonic machines would have 
allowed us to calculate the maximum specific and personalized load to use for each 
patient and therefore we could have adapted and increased the training stimulus more 
effectively with muscle strengthening exercises. By doing so, we could have obtained 
better results in the different outcomes related to the physiological parameters under 
consideration. 
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5. Conclusions 
 
In conclusion, the results of the present pilot study showed that the supervised exercise 
program was able to make significant changes in terms of aerobic capacity, muscle 
strength, perceived fatigue and quality of life. We were able to ascertain that many of the 
consequences of the disease, such as muscle weakness, fatigue and depression, were 
largely due to de-conditioning. The positive effects obtained in terms of physical and 
mental conditioning were sufficient to avoid cases of drop-out during the entire period of 
intervention. This pilot study with a training program of this type and duration, is a 
possible useful model for an applicable everyday exercise protocol and can also be 
propose in hospitals that offer limited-equipped gym. 
Future studies on BCS should consider proposing the exercise protocol for a longer 
period both for BCS and for patients undergoing treatment. Furthermore, based on the 
availability of hospital resources, future exercise protocols could be based on maximal 
testing. 
The approach to cancer patients must include, in addition to specific medical therapies, 
particular attention to the communicative and relational dimensions. For the cancer 
patient, exercise can help patients to cope better with the post-surgery phase and foster 
recovery, both physically and psychologically, after the debilitating treatment phase. 
For the BC patients, the "post-surgery" phase is a long and difficult period from a 
psychological point of view, and it includes frequent checkups and follow-ups: the 
inclusion of care programs can help to create a physio-psychological support network 
during this delicate/difficult phase. An exercise promotion activity involving PA 
counseling and a supervised exercise program also provides opportunities to socialize in 
groups, a fundamental element from a psychological standpoint. In fact, BC patients often 
tend to isolate themselves following diagnosis: having a personalized health plan that also 
helps the patient to avoid isolation and to face and share with the other patients their 
difficulties can be an important resource for the patient in facing daily challenges. 
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“Dragonette” – An example of a project for women who have undergone breast 
cancer surgery, which shows a high level of adherence to the exercise program 
 
Today we can no longer think that women who have undergone surgery following a 
diagnosis of breast cancer will not return to a full and active life. There is growing 
scientific interest in the types of exercise that can best play a role both in terms of 
primary and secondary prevention of breast cancer, and women who have undergone 
surgery following diagnosis of breast cancer are becoming more and more aware of the 
benefits of an active lifestyle. Many of these "active" women are now part of an 
important project called "Abreast in a Boat", an initiative started in 1996 in Canada, at the 
behest of Dr. Don McKenzie. 
This project is for women who have undergone breast cancer surgery with the aim of 
debunking the myth that, for those who have undergone partial or total breast removal 
due to cancer, it is not possible to engage in physical activity given the very high risk of 
lymphedema. The project, therefore, started with a group of volunteers who engaged in 
an activity that essentially involved using the arms and the bust. The project has since 
been  adopted in many countries in the Americas and Europe. In Italy, the first team of 
women in pink was founded in Rome in 2003 and a group of breast cancer survivors in 
Turin have been involved in dragon boating for years. 
The women who participate in this project are called Dragonettes because of the type of 
boat that is used. In fact, the 12.66-meter long dragon boat is an ancient boat of Chinese 
origin with the head and the tail in the shape of a dragon; the paddles are similar to those 
of the Canadian canoe and weigh about 1 kg. There are 20 athletes in the boat, 10 on the 
right and 10 on the left, with the helmsman and a drummer. At the bow, facing the crew, 
a drummer beats time on a large drum, while at the stern is the helmsman, right on the tail 
of the dragon, struggling with 3-meter long oars. 
Today, Dragonette crews are able to participate in events and non-competitive dragon 
boat races, and they are also supported by women who have not undergone surgery who 
train with the "otherwise lucky" (as the Dragonettes call themselves) and this has made it 
possible to form solid teams. Indeed, the Dragonettes have already been recognized by 
the Italian Dragon Boat Federation, as the women in pink section. 
Rowing to fight breast cancer is a challenge that the women of the Marche region have 
also met. On 22 July 2018 the first dragon boat of the Marche, promoted by the 
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Department of Medical Oncology, University Hospital of Ancona and the Fondazione 
Ospedali Riuniti of Ancona, in collaboration with other local companies, took part in a 
joyous sporting event dedicated to women with breast cancer. The aim of the event was 
to raise awareness of breast cancer prevention, emphasizing the importance of respecting 
the calendar of checkups/screening and pledging support for all women affected by the 
disease. 
Twenty breast cancer survivors took part in the event and ten of them had taken part in 
the “Lifestyle program” coordinated by the Oncologists of the Breast Cancer Unit, 
University Hospital of Ancona. This crew of Dragonettes, has also ventured with its own 
boat on a journey of about 6 km in the Adriatic Sea. 
Sport and medicine are coming together more and more: the specific breast cancer 
guidelines of the ACSM show that this activity, although not empirically tested, is a valid 
safe form of exercise given the large number of women who take part in Dragon Boating. 
Paddling is very useful for the full recovery of the upper limbs. But even more important 
are the psychological benefits: sharing, teaming up, discovering, getting back into the 
game, even at a difficult time, setting new goals to be stronger than before. Side by side 
in a boat, to win in life. 
 
 
Dragonettes – “Side by side in a boat, to win in life”. First Dragon Boat of the Marche 
region, Italy, 22 July 2018. 
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Nothing makes a woman more fragile and vulnerable than the onset of a serious illness. 
When the diagnosis is "breast cancer", the negative connotations associated with this 
pathology generate the impression of being invaded and overwhelmed by something 
malignant. It was in this particular scenario, that the role of exercise in primary and 
secondary cancer prevention was examined. In addition, the possible mechanisms 
activated and/or regulated by exercise were identified and investigated by examining 
recent evidence regarding the effects of muscle contraction on the inhibition of the 
mTOR pathway in a particular subtype of BC, TNBC. In this regard, a group of young 
healthy women were recruited to perform acute endurance exercise (high-intensity 
endurance cycling (HIEC)) and we investigated how the circulating serum factors 
released after exercise can reduce TNBC cell proliferation, in vitro. We showed that a 
single exercise session exerted a significant protective effect against tumor proliferation 
in triple-negative cell lines. In addition, we revealed how the proposed training led to 
systemic changes, including the exertion of inhibitory effects on the viability of the 
analyzed BC cell line. 
Given the growing body of evidence regarding the importance of lifestyle changes for 
women diagnosed with BC (before, during and after the long therapeutic journey), we 
investigated the effect of structured and supervised PA in BCS in collaboration with the 
Breast Cancer Unit, University Hospital of Ancona, within the "Lifestyle Program", 
which promotes exercise in the therapeutic treatment of BC. 
In this context, we stressed that PA counseling can motivate women with BC to adopt a 
healthier lifestyle, helping them to maintain PA levels that are recommended by the 
guidelines for this population. However, changing one’s lifestyle is a complex process: 
providing information is not enough, and it does not ensure the implementation of a PA 
program. In fact, a social support network is needed, allowing these patients to embark on 
a personalized journey and providing them with support at every stage of the disease. 
Indeed, as the data of our pilot study show, an approach involving the promotion, 
prescription and administration of a structured and supervised training program, 
represents an important step in changing patients’ lifestyles and improving their quality 
of life. 
Hence, PA can only be promoted effectively by creating a support system, involving 
various professionals, including oncologists; physiatrists; physiotherapists; graduates in 
physical education, exercise and sports science; nutritionist and psychologists. The 
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multidisciplinary interventions of these professionals provide a coordinated program of 
care for the patient, creating the proper conditions for the promotion and practice of PA, 
which is vital for the prevention and treatment of female tumors. 
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